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DIRAS3 is a maternally imprinted tumor suppressor gene that is downregulated by 
multiple mechanisms across several tumor types. When re-expressed, DIRAS3 
decreases proliferation, inhibits motility, and induces autophagy and tumor dormancy. 
DIRAS3 encodes a 26 kDa small GTPase with 60% homology to Ras and Rap, differing 
from oncogenic Ras family members by a 34-amino acid N-terminal extension that is 
required for its tumor suppressive function in ovarian cancer. By assessing the 
structure-function relationship, I found that DIRAS3 inhibits Ras-induced 
transformation and is a natural antagonist of Ras/MAPK signaling. DIRAS3 binds 
directly to Ras and disrupts cluster formation inhibiting the activation of Raf kinase, 
which is dependent upon membrane localization and the N-terminal extension. This 
observation provides a novel approach to target oncogenic Ras and assesses the 
functional significance of Ras clustering/multimerization.  
The N-terminus of DIRAS3 also plays an important role in the mechanism(s) by which 
DIRAS3 induces autophagy. Expression of DIRAS3 is required for the induction of 
autophagy in human cells. While DIRAS3 is found in the genome of humans, pigs and 
cows, it maps to an apparent evolutionary breakpoint in the rodent lineage where 
chromosomes have been rearranged relative to the human genome since the two 
species shared a common ancestor. Mice and humans do express two homologous 
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Ras-related GTPases, DIRAS1 and DIRAS2. These 22-kDa GTPases have 30-40% 
homology with H-Ras and 50-60% homology with DIRAS3 where the major difference 
is the truncation of the N-terminal extension. DIRAS1 and DIRAS2 have not previously 
been studied extensively. I compared the roles of the DIRAS family in malignant 
transformation, proliferation, survival, motility and autophagy. My observations 
document the role of DIRAS1 and DIRAS2 as ovarian cancer tumor suppressors and 
demonstrate their role in autophagy and autophagic cell death. Similar to DIRAS3, 
DIRAS1 and DIRAS2 induce autophagy at several different levels, including 
transcription-dependent mechanisms. DIRAS1 and DIRAS2 likely serve as surrogates 
for DIRAS3 in the murine genome, playing an essential role in murine autophagy. 
These studies are fundamentally important as they explore the functional significance 
of their N-terminal extensions, helping to explain how members of an oncogenic 
superfamily acquire tumor suppressor function.  
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Cancer is a disease driven by genetic alterations that control how cells function with 
regard to cell proliferation, programmed cell death, motility and metastasis. Throughout decades 
of research, our understanding of this complex disease has provided insight into the fundamental 
mechanisms of tumor development, the multistep process of tumor pathogenesis and 
dissemination, and the contributions of the tumor microenvironment which collectively enable 
tumor growth. These genetic alterations include mutations, deletions, and gene amplifications, 
which can arise from a number of stimuli including carcinogen exposure and errors during cell 
replication. Often these genetic alterations target tumor suppressor genes and proto-oncogenes. 
Tumor Suppressor Genes. Tumor suppressors are generally regarded as genes that limit cell 
proliferation, induce cell death, repair DNA damage or prevent invasion and metastasis. As a 
counter balance to growth promoting genes, they provide key checkpoints to ensure replication 
occurs when DNA damage has been repaired or to activate programmed cell death when 
necessary. While there are many mechanisms by which tumor suppressor genes and their 
encoded proteins work, the one thing they all have in common is the ability to reduce the 
likelihood of neoplastic transformation. The first tumor suppressor gene, Rb1 was identified by 
Benedict, Cavanee, Sparkes and colleagues studying a rare childhood eye tumor, 
retinoblastoma. (Benedict, Murphree et al. 1983, Cavenee, Dryja et al. 1983, Sparkes, Murphree 
et al. 1983) The observation that retinoblastomas could arise in a statistically viable model where 
inactivation of both alleles of RB1 was required for oncogenesis, explaining the involvement of 
both eyes with inherited familial disease, but only one eye in sporadic cases provided the first 
direct evidence of genetic loss of tumor suppressors. (Knudson 1971) This was later referred to 
as the two-hit hypothesis, in which Knudson and colleagues document that two inactivating “hits” 
must occur in a tumor suppressor gene for the cancer to arise, since often times a single 
functional tumor suppressor gene can be sufficient to protect from cancer development without 
additional insults to DNA. One particularly well studied tumor suppressor gene is TP53, the 
second ever discovered and also known as the “guardian of the genome.” (Baker, Fearon et al. 
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1989) P53 had a well-known role in cancer development for at least a decade before its true 
function was identified. It was documented that the p53 mutations which arose in transformed 
cells were identical to those seen in human cancer cases, suggesting that they were inactivating 
mutations likely working in a dominant-negative manner, and solidifying the role of p53 as a tumor 
suppressor. (Finlay, Hinds et al. 1989, Baker, Markowitz et al. 1990) Functionally, p53 uses 
several mechanisms to protect cells from uncontrolled proliferation, but best characterized is its 
role as a transcriptional activator. In a context dependent manner, p53 dictates whether a cell 
will undergo cycle arrest allowing for DNA repair, or trigger apoptotic cell death when stress 
signals and irreparable damage occur. (Kastan and Bartek 2004) Recent reports have also 
implicated a tumor suppressive role for p53 in response to oxidative stress, nutrient deprivation, 
hypoxia, and others by activating several intracellular pathways including senescence, 
autophagy, metabolism, and DNA repair. (Bieging and Attardi 2012) Whereas TP53 function is 
largely determined by intracellular sensors of stress and DNA damage from within the cell, RB 
halts cell proliferation from signals that are transduced from extracellular stimuli. (Hanahan and 
Weinberg 2011) Currently, there are four major mechanisms known by which tumor suppression 
occurs 1) cell cycle arrest and suppression of cell division, 2) induction of cell death cascades 
including apoptosis, 3) repairing DNA damage and 4) inhibiting metastasis. Despite the 
identification of more than 600 human tumor suppressor genes, thusfar none have been shown 
to bind directly to an oncogene and reverse its function.   
Oncogenes. In addition to loss of tumor suppressor function, cancers may arise by activation of 
certain normal regulatory genes through one of the following 1) mutation, 2) overexpression of 
wild-type protein through gene amplification or 3) expression of a fusion protein produced by 
translocation to a gene under the influence of a strong promoter. Activated “oncogenes” drive 
persistent cell proliferation, enhance resistance to cell death, alter metabolism, and increase 
motility, invasion and metastasis. Evidence that viruses can cause cancer dates to the early 
1900’s when Peyton Rous identified the first cell-free filtrate from a tumor homogenate that could 
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lead to new tumor development upon transplantation from one hen to another. (Rous 1910, Rous 
1911) Discovery of the Rous sarcoma virus (RSV) opened the study of oncogenic retroviruses 
which were found to contain regulatory genes from mammalian cells. By the late 1970’s, there 
was a growing consensus that cancer is a disease of genetically altered genes. Work by 
Weinberg, Cooper and colleagues demonstrated that chemically mutating the genome could 
result in transforming ability in the absence of any viral involvement, but the precise identity of 
the transforming gene remained elusive. (Shih, Shilo et al. 1979, Cooper and Neiman 1980) In 
1982, the concept of cellular oncogenes were confirmed by cloning Ras from a rat sarcoma 
where a normal cellular signaling protein was activated by mutation, laying the groundwork for 
much of our modern understanding of cancer and the genetic aberrations that drive oncogenesis. 
(Der, Krontiris et al. 1982, Goldfarb, Shimizu et al. 1982, Parada, Tabin et al. 1982, Pulciani, 
Santos et al. 1982, Reddy, Reynolds et al. 1982, Santos, Tronick et al. 1982, Shih and Weinberg 
1982, Tabin, Bradley et al. 1982, Taparowsky, Suard et al. 1982)  
Ras Oncogenes. Ras has become one of the most intensively studied oncogenes, not only 
because it regulates normal cell functions, but also for its role in malignant transformation and 
cancer progression. Mutant Ras is associated with approximately 30% of all human cancers, 
including 95% of pancreatic cancers, 60% of low grade epithelial ovarian cancers and 35% of 
lung cancers. (Singer, Oldt et al. 2003, Prior, Lewis et al. 2012) Ras belongs to a class of proteins 
that hydrolyze GTP to GDP designated GTPases, which now include more than 150 family 
members. (Wennerberg, Rossman et al. 2005) Three distinct Ras genes encode four ~21 kDa 
proteins including H-Ras, N-Ras, K-Ras4a and K-Ras4b (Figure 1A). The conformational 
changes which occur in Ras proteins upon binding GTP or GDP serve as a switch that regulates 
signaling from cell surface receptors through several different cytoplasmic signaling cascades 
that influence proliferation, apoptosis, motility and metabolism. Small GTPases like Ras, contain 
a highly conserved domain composed of a six-stranded β-sheet surrounded by five α-helices 
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which contains the guanine nucleotide binding site. (Cherfils and Zeghouf 2013) This molecular 
switch depends not only on the intrinsic GTPase activity, but also on guanine nucleotide 
exchange factors (GEFs) that stimulate the exchange of GDP and GTP and GTPase-activating 
proteins (GAPs) that increase intrinsic GTP hydrolysis (Figure 1B). The GDP-bound form of Ras 
is often considered inactive, whereas the GTP-bound form of Ras undergoes a conformational 
change which facilitates binding of other downstream effector molecules leading to the activation 
of various signaling cascades. In the case of Ras, the four isoforms are not mutated with equal 
frequency, adding to the complexity of the isoform specific roles in oncogenesis. The somatic 
mutations that occur most frequently decrease GTPase activity, preserving GTP binding and 
locking the Ras protein into an ‘on’ state. Oncogenic substitutions at glycine 12 or 13 disrupt the 
van der Waals interaction between Ras and the associated GAP protein perturbs the orientation 
of the catalytic glutamine (Q61) attenuating GTP hydrolysis (Figure 1C). (Scheffzek, Ahmadian 
Figure 1. Ras GTPases are molecular switches that activate cellular signaling cascades 
based on their nucleotide binding. A. Ras isoforms differ primarily in sequence homology 
at their C-terminal domain. Cartoon illustration that highlights common Ras motifs and the 
sequence homology between the three Ras isoforms, H-Ras, N-Ras and K-Ras4b. B. Ras is 
a molecular switch that is inactive when bound to GDP and active when bound to GTP. GAPs 
and GEFs help facilitate the exchange between nucleosides. C. Crystal structure model 
adapted from Lu et. al. 2016 and Prior et al. 2012 of H-Ras-GTP highlighting the key amino 
acid residues (G12, G13, Q61) that coordinate with the GAPs to facilitate hydrolysis, and are 
often found mutated in human cancer. 
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et al. 1997, Prior, Lewis et al. 2012, Lu, Jang et al. 2016) Similarly, oncogenic point mutations of 
Q61 have been observed in human cancers, resulting in an uncoordinated water molecule which 
is critical to the nucleophilic attack of the γ- phosphate, once again decreasing GTPase activity 
and maintaining bound GTP. (Scheidig, Burmester et al. 1999, Buhrman, Holzapfel et al. 2010) 
GAP-catalyzed GTP hydrolysis of Ras is dependent upon the glutamine in this motif and while 
this is true of other small GTPases, it is not essential for all. These subtle changes in sequence 
homology and function allow for the separation of small GTPases into five major subgroups. 
Each subfamily has GEFs, GAPs, and for some guanosine nucleotide dissociation inhibitors 
(GDIs), which specifically associate with and modulate the major biological functions of each 
group resulting in sophisticated autoregulatory mechanisms which are still being elucidated. 
(Cherfils and Zeghouf 2013) Regulation of Ras by tumor suppressors has received much less 
attention. One goal of this dissertation is to elucidate the ability of the DIRAS family members to 
inhibit Ras-induced transformation of murine fibroblasts and human mammary epithelial cells as 
well as reveal how the interaction between DIRAS3 and Ras affects its binding to other well 
established proteins essential to the signaling cascade, such as Raf and Sos-1. 
DIRAS Tumor Suppressor Genes. The Distinct subgroup of the Ras family (DIRAS) is a Ras-
related group of three small GTPases including DIRAS1, DIRAS2 and DIRAS3. DIRAS family 
members have not been studied as extensively as the Ras proteins. In contrast to Ras, DIRAS3 
has been functionally characterized as a tumor suppressor in ovarian cancer. DIRAS3 is a 
maternally imprinted gene that was found to be markedly downregulated in the majority of ovarian 
cancers when compared to normal ovarian epithelial cells. (Yu, Xu et al. 1999) Downregulation 
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has been shown to be mediated by several different mechanisms described below. (Yu, Xu et al. 
1999, Feng, Marquez et al. 2008) Sharing 50-60% homology to Ras and Rap, DIRAS3 is a ~26 
kDa small GTPases which differs primarily in the 
addition of a 34-amino acid N-terminal extension, 
which is essential for most functions. (Luo, Fang et 
al. 2003) (Figure 2) Previous work from the Bast 
laboratory and others provided the molecular basis 
whereby DIRAS3 inhibits cell growth and motility, 
induces autophagy and establishes tumor 
dormancy. (Yu, Xu et al. 1999, Luo, Fang et al. 
2003, Lu, Luo et al. 2008, Lu, Baquero et al. 2014, 
Lu, Yang et al. 2014) While many of the previously 
reported functions of DIRAS3 support its role in 
tumor suppression, classical experiments to 
demonstrate this in knockout mouse models is not possible due to lack of DIRAS3 in the murine 
genome. (Fitzgerald and Bateman 2004) Both mice and humans do, however, express DIRAS1 
and DIRAS2. DIRAS1 and DIRAS2 proteins share 30-40% overall amino acid homology with 
Ras and Rap and 50-60% homology with DIRAS3 where the only major difference is the 
truncation of the N-terminal extension from 34-amino acids to 4-amino acids. DIRAS1 and 
DIRAS2 are ~22 kDa proteins that have not been studied extensively. Only two reports have 
documented their impact on tumor progression. (Ellis, Vos et al. 2002, Zhu, Fu et al. 2013) Most 
recently, Bergom and colleagues described a tumor suppressive mechanism for DIRAS1, finding 
that its interaction with SmgGDS antagonizes the guanine nucleotide exchange factor and 
inhibits its binding to other small oncogenic GTPases. (Bergom, Hauser et al. 2016)  
As an imprinted gene, DIRAS3 is expressed only from the paternal allele and expression 
is lost or silenced in ovarian cancer by several mechanisms including 1) loss of heterozygosity 
Figure 2. DIRAS family GTPases 
differ primarily in the length of their 
N-terminal extension. A cartoon 
depicting the DIRAS family protein 
structures as compared to H0Ras and 
a table of functions of DIRAS3 and 
ΔNT DIRAS3. 
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(~60%), 2) transcriptional and miRNA regulation (~10%), or 3) hypermethylation of the paternal 
as well as the maternal allele (~30%). (Feng, Marquez et al. 2008) (Figure 3) In addition to 
ovarian cancers, 
downregulation of 
DIRAS3 has been 
demonstrated in 
carcinomas of the 
pancreas, lung, breast, 
thyroid, prostate and liver. 
(Weber, Aldred et al. 
2005, Yu, Luo et al. 2006, 
Dalai, Missiaglia et al. 
2007, Huang, Lin et al. 
2009, Lin, Cui et al. 2011, 
Wu, Liang et al. 2013) Previous work from the Bast laboratory and others, has demonstrated that 
re-expression of DIRAS3 inhibits growth, slows motility and invasion, induces autophagy and 
establishes tumor dormancy.  
Much of this work has focused on the mechanisms by which DIRAS3 plays an essential 
role in the induction of autophagy by 1) inhibiting the PI3K/AKT/mTOR signaling pathway, 2) 
participating in the autophagy initiation complex, 3) decorating autophagosomes, and 4) 
regulating the nuclear localization of FOXo3a, a master autophagy-related transcription factor. 
(Yu, Luo et al. 2006, Lu, Luo et al. 2008, Lu, Baquero et al. 2014, Lu, Yang et al. 2014) DIRAS3-
induced autophagy can also sustain survival of dormant ovarian cancer xenografts, and 
disruption of autophagy with chloroquine, a functional inhibitor, significantly delayed outgrowth 
of tumors following downregulation of DIRAS. (Lu, Luo et al. 2008) 
Figure 3. The imprinted tumor suppressor gene, DIRAS3 is 
downregulated by several mechanisms. 
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 Autophagy. The process of autophagy, or cellular self-digestion, has been well characterized 
in both yeast and mammalian systems, documenting the dynamic process by which a cell can 
sequester and degrade cytosolic proteins and organelles, releasing amino acids and fatty acids 
to provide energy in nutrient poor conditions. (Cecconi and Levine 2008, Reggiori and Klionsky 
2013) Unlike the ubiquitin-proteasome pathway, which targets individual short-lived proteins, 
autophagy functions as a bulk process capable of degrading the endoplasmic reticulum, 
mitochondria, peroxisomes, the nucleus and ribosomes. (Mizushima and Klionsky 2007, Stolz, 
Ernst et al. 2014) This tightly regulated catabolic process is more broadly classified into three 
types: macroautophagy, microautophagy and chaperone-mediated autophagy. In 
macroautophagy, cellular components are packaged in double-membrane vesicles that fuse with 
lysosomes, where acidification occurs and proteins and lipids are cleaved by hydrolases to 
release amino- and fatty acids. (Komatsu, Waguri et al. 2007) Microautophagy occurs when 
cytoplasmic content is directly engulfed by the lysosome following invagination of the lysosomal 
or endosomal membrane and then degraded by lysosomal proteases. (Li, Li et al. 2012) 
Chaperone-mediated autophagy (CMA) results in degradation of specific cargo that contains a 
pentapeptide motif ‘KFERQ-like’ which can be recognized by specific cytosolic chaperones and 
translocate the cargo directly to the lysosome via the lysosomal-associated membrane protein 
2a (LAMP2A) without the formation of a membrane vesicle. (Cuervo and Wong 2014)  
Macroautophagy, henceforth referred to as autophagy, is the best characterized of the three 
processes. A large body of work spanning several decades has provided detailed molecular 
mechanisms and insight into how this process occurs. The first of the autophagy-related genes 
(ATG) was discovered in yeast, and now some 30 autophagy-related proteins have been 
identified in yeast and in mammalian cells, of which about half are thought to be involved in the 
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highly conserved canonical autophagy shared by all organisms. (Lamb, Yoshimori et al. 2013) 
Autophagy is characterized by six sequential steps; initiation, nucleation, elongation, maturation 
of the autophagosome, fusion and degradation. These steps begin with the sequestration of the 
cytoplasmic materials and end with lysosomal breakdown. (Figure 4) 
Biogenesis of autophagosomes is initiated by a phagophore assembly complex that 
contains ULK1/2, ATG13, FIP200 and ATG101 and is regulated by the UNC51-like kinase (ULK). 
Autophagy can be induced by several mechanisms, including downregulation of p-mTOR, which 
negatively regulates the ULK complex by interacting with and phosphorylating ULK1/2 and 
ATG13. (Vucicevic, Misirkic et al. 2011) Decreased p-mTOR levels result in dissociation of 
mTORC1 from the ULK complex resulting in partial dephosphorylation of p-ULK triggering 
localization of the phagophore and ULK1/2-mediated phosphorylation of ATG13, FIP200 and 
itself (ULK). (Glick, Barth et al. 2010) Further induction of autophagy requires the formation of an 
autophagosome initiation complex (AIC) which includes Beclin1 (BECN1), class III 
Figure 4. Autophagy is a multistep process that is mediated by several key regulators, 
including Beclin1, DIRAS3, LC3, and ATGs. 
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phosphatidylinositol 3-kinase (PI3K), VPS34, p150, ATG14 and DIRAS3. (Hosokawa, Hara et al. 
2009, Matsunaga, Saitoh et al. 2009, Lu, Baquero et al. 2014) In well fed cells, BECN1 dimers 
bind to Bcl-2 that prevents interaction with other components of the AIC. Following nutrient 
deprivation, DIRAS3 is upregulated and dissociates BECN1 dimers resulting in their dissociation 
from Bcl-2 (Lu, Baquero et al. 2014). Thus, permitting BECN1 monomer to bind with 
phosphatidylinositol 3-kinase catalytic subunit type 3 (PIK3C3) and VPS34. (Matsunaga, Saitoh 
et al. 2009) Subsequently, ATG14 associates with the AIC and directs it to a phagophore 
assembly site. (Itakura, Kishi et al. 2008, Sun, Fan et al. 2008, Matsunaga, Saitoh et al. 2009) 
Following nucleation, elongation of the autophagosomes occurs in a multistep ubiquitin-like 
conjugation process involving many of the ATGs and the LC3-PE complex. (Glick, Barth et al. 
2010, Sridharan, Jain et al. 2011) The conversion of LC3 I to LC3 II is often used as a surrogate 
to document the elongation and formation of the autophagosome. (Klionsky, Abdelmohsen et al. 
2016) Simultaneously, p62 binds and targets damaged proteins and organelles for degradation 
in the autophagolysosome and its decreased expression is associated with increased autophagic 
flux. (Klionsky, Abdelmohsen et al. 2016) DIRAS3 also decorates the autophagosomes and can 
be cross-linked to LC3-II. With its cargo engulfed, the autophagosome docks and fuses with the 
lysosome which was discovered in 1955 by de Duve and colleages, forming the 
autophagolysosome, where degradation and recycling of amino and fatty acids provides energy 
in the form of ATP for nutrient-deprived cells.  
Role of Autophagy in Normal Tissues and in Cancer. Some tissues like the heart, 
muscle, brain and liver are more dependent on autophagy to manage the buildup of damaged 
proteins and mitochondria. (Mizushima and Komatsu 2011) As a method to maintain cellular 
integrity, autophagy can mitigate ER stress and provide essential nutrients for yeast and 
mammals to survive starvation by recycling components into metabolic pathways. (Hoyer-
Hansen and Jaattela 2007, Rabinowitz and White 2010) By breaking down lipids into fatty acids, 
autophagy provides catabolites for the TCA cycle resulting in ATP production. Likewise, the 
 
12 
    
breakdown of damaged proteins and organelles provides amino acids for protein synthesis and 
also fuels the TCA cycle, also resulting in ATP production. Autophagy can also generate glucose 
from glycogen resulting in nucleotide and fatty acid biosynthesis from the pentose phosphate 
pathway (PPP). (Kaur and Debnath 2015) (Figure 5) Autophagy deficiency is speculated to 
contribute to the pathogenicity of several diseases including neurodegenerative diseases, liver 
disease and aging. (Levine and Kroemer 2008) In cancer, the role of autophagy remains more 
ambiguous as some reports document a clear tumor suppressive phenotype during oncogenesis 
while others suggest the role of autophagy can promote oncogenesis by sustaining fully 
transformed nutrient-deprived cancer cells. (Cecconi and Levine 2008, White 2015) Likely, these 
phenotypes are dependent upon the context in which autophagy operates. Clinical trials have 
been undertaken with 
hydroxychloroquine, a strongly 
basic lipophilic drug that penetrates 
autophagolysosomal membranes 
and decreases the acidification of 
their contents, preventing hydrolysis 
of proteins and lipids, functionally 
inhibiting autophagy. Promising 
studies which demonstrated 
antitumor activity and improved 
clinical outcomes have been 
ongoing for several disease sites 
including melanoma, myeloma, colorectal cancer and renal cell carcinoma. (Mahalingam, Mita 
et al. 2014, Rangwala, Chang et al. 2014, Rangwala, Leone et al. 2014, Rosenfeld, Ye et al. 
2014, Vogl, Stadtmauer et al. 2014, Patel, Hurez et al. 2016) In ovarian cancer, autophagy has 
been shown to play a critical role in the survival of dormant disease. 
Figure 5. Autophagy provides metabolites for 
many cellular functions. Autophagy can breakdown 
lipids, damaged proteins, organelles and glycogen to 
fuel different metabolic pathways under stressful or 
nutrient poor conditions which can both support and 
suppress tumor growth. 
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Ovarian Cancer. Clinically, epithelial ovarian cancers arise from flattened mesothelial cells that 
cover the surface of the ovary, from similar cells that line cysts immediately beneath the ovarian 
surface or from the cells that cover the fimbriae of the fallopian tube. (Crum, Drapkin et al. 2007) 
Like other solid tumors, ovarian cancers can metastasize through the blood or lymph, but most 
frequently metastasize across the abdominal cavity forming multiple tumor nodules on the 
parietal and visceral peritoneum.  
Ovarian cancer is classified into two subgroups, type I and type II. Type I ovarian cancer 
refers to low grade cancers which typically grow slower and are diagnosed at an early stage (I-
II). Low grade ovarian cancers are generally characterized by their stable genome, often being 
driven by activating mutations in Ras (60%) or PI3K signaling pathways and stimulation by 
insulin-like growth factor (IGF). Low grade cancers are also characteristically resistant to 
conventional chemotherapies. Type II ovarian cancers are high grade cancers which are more 
aggressive and often diagnosed in at late stage (III-IV). High grade serous ovarian cancer is the 
most common type of ovarian cancer and makes up the majority of Type II cancers, which are 
characterized by genomic instability, amplification of PIK3CA and AKT, and mutations in TP53 
(>97%) and BRCA1/2 (15% germ line and 5% somatic). When high grade serous ovarian cancer 
is diagnosed early (where the disease is still confined to the ovary) more than 90% of patients 
can be cured with currently available therapy, including cytoreductive surgery and chemotherapy 
with a combination of carboplatin and paclitaxel. When the disease has disseminated, the long 
term survival drops drastically to ~30%. (Aletti, Dowdy et al. 2007, Espey, Wu et al. 2007, 
Ashworth, Balkwill et al. 2008) Treatment with six cycles of paclitaxel and carboplatin will produce 
a response in 70% of patients, but less than 30% will remain free from recurrence. While median 
survival now extends to 4-5 years with optimal and aggressive care, the fraction of women cured 
remains less than 30% and this has not changed over the last three decades. (Sutton 2014)  
Autophagy in Human Ovarian Cancer. Previously, “second-look” operations were performed 
after primary surgery and chemotherapy to detect residual disease on the peritoneal cavity, but 
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due to lack of available treatment options for “positive second-looks” these operations have since 
been abandoned, but are now being reinstituted. These small deposits of disease were often 
found in small, poorly vascularized fibrotic nodules on the surface of the peritoneum, and analysis 
of these tumors revealed high expression of DIRAS3 and correlated with LC3 punctate and 
Beclin1 expression in >80% of cases, which are characteristic features of autophagic cells. (Lu, 
Baquero et al. 2014) In this setting, ovarian cancer cells are likely to be hypoxic and nutrient 
deprived where autophagy can have a positive impact to supply nutrients and maintain tumor 
dormancy. Efforts to modulate this balance are currently being explored in the Bast laboratory.  
Autophagy in Murine Cells. In addition to the role in cancer, autophagy plays a critical role 
during embryogenesis and postnatal development, as determined by the developmental 
phenotypes resulting from genetically engineered mouse models with deficits in key autophagy 
related genes. (Cecconi and Levine 2008) Despite the absence of DIRAS3, which was lost during 
the evolution of mice, but retained in humans, pigs and cows, during a telomeric chromosomal 
re-arrangement that occurred ~60 million years ago, murine cells still have the ability to undergo 
autophagy. (Fitzgerald and Bateman 2004, An, Zhao et al. 2012, Shin, Lim et al. 2012, Kang, 
Louboutin et al. 2013) Both mice and humans express the two homologous DIRAS family 
members, DIRAS1 and DIRAS2. This dissertation addresses the role of DIRAS1 and DIRAS2 in 
regulating growth and survival of ovarian cancers, and more importantly, explores whether these 
GTPases serve as surrogates to DIRAS3 in the murine genome, playing an essential role in 
autophagy. 
Aims and Hypotheses of the Study. The first goal of this study was to identify the structural 
features of DIRAS3 that are required to block mutant H-Ras- and K-Ras-driven malignant 
transformation of murine 3T3 cells and of partially transformed MCF10a breast epithelial cells. 
Experiments described in Chapter 3 demonstrate that DIRAS1, DIRAS2 and DIRAS3 inhibit H-
Ras- and K-Ras-induced transformation in both cell types and DIRAS1, DIRAS2 and DIRAS3 
are natural antagonists of Ras/MAPK signaling. These studies tested the hypothesis that 
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inhibition of malignant transformation is due to a direct interaction of DIRAS3 with Ras and that, 
in addition to binding, the N-terminus and CAAX-membrane anchoring domains of DIRAS3 are 
required. Chapter 4 explores the mechanism by which DIRAS3 inhibits growth of Ras-driven 
cancers and diminishes downstream ERK signaling. We tested the hypothesis that DIRAS3 
inhibits Ras activity by binding directly to Ras and disrupting Ras multimerization and clustering. 
DIRAS1 and DIRAS2 also inhibit Ras multimerization. These observations provide the first 
example of direct interaction of a tumor suppressor with the oncogene that it suppresses and, 
moreover, identify the first endogenous protein to disrupt Ras clustering and activity. In addition 
to exploring the functional significance of DIRAS3 structure, this work holds translational promise. 
Peptides or small molecules that mimic DIRAS3 activity could target the function of mutant Ras 
directly and specifically, filling a significant unmet clinical need to target mutant Ras in multiple 
types of cancer.  
A second aim was to define the role of DIRAS1 and DIRAS2 in regulating proliferation, 
survival and migration of human ovarian cancer cells. In Chapter 5, expression of DIRAS1 and 
DIRAS2 was measured in multiple tissues and organs, and downregulation of DIRAS1 and 
DIRAS2 was documented for the first time. In chapter 6, we tested the hypothesis that re-
expression of DIRAS1 or DIRAS2 will inhibit proliferation and survival by inducing autophagic 
programmed cell death, but not by apoptosis, cell cycle arrest or senescence. The ability of 
DIRAS1 and DIRAS2 to inhibit growth of ovarian cancer cell growth was documented in cell-
based assays and in experimental xenograft models. We also determined that DIRAS1 and 
DIRAS2 inhibit cell motility. Collectively, these data build a case for the role of DIRAS1 and 
DIRAS2 as tumor suppressors.  
A third goal wass to determine the role of DIRAS1 and DIRAS2 in regulating autophagy 
in both human and murine cancer cells. In human cancer cells, re-expression of DIRAS3 induces 
autophagy and is required for the induction of autophagy. DIRAS3 has been lost from the murine 
genome, but autophagy is still observed in mice. We tested the hypothesis that DIRAS1 and 
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DIRAS2 serve as surrogates for DIRAS3 and promote autophagy in mice. To examine the 
mechanism(s) by which DIRAS1 or DIRAS2 induce autophagy, we tested whether re-expression 
of DIRAS1 or DIRAS2 inhibit key signaling pathways resulting in transcriptional upregulation of 
autophagy-related genes. Re-expression of DIRAS1 or DIRAS2 decreased signaling through 
Ras/MAP and PI3K and increased nuclear localization of FOXo3a and TFEB as described in 
Chapter 7. In Chapter 8, murine DIRAS1 and DIRAS2 induced autophagy in murine ovarian 
cancer cells and knockdown of DIRAS1 and DIRAS2 blocked autophagy induced by amino acid 
starvation, supporting the possibility that DIRAS1 and DIRAS2 serve as surrogates for DIRAS3 
in the murine genome. Homozygous knockout of DIRAS1 and DIRAS2 produced early embryonic 
lethality in mice, consistent with an important role for autophagy in normal embryonic 
development. In Chapter 9, these findings are discussed as are the future implications of this 
work.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
18 
    
Cell Lines and Reagents. NIH3T3 Mouse fibroblast cells, AsPc-1, Capan-2, Panc-1, MiaPaca2, 
Su86.86 pancreatic cancer cells, H358 and H441 lung adenocarcinoma cells and SKOv3 ovarian 
cancer cells were obtained from the ATCC; MCF10a, OVCAR8 and Hey-A8 cells were provided 
by Dr. Gordon Mills, UT MD Anderson Cancer Center (Houston, TX); AsPc-1 cells were obtained 
from ATCC; TKOOV10, ID8, and IG10 cells were provided by Dr. Samuel Mok, UT MD Anderson 
Cancer Center;  RCME-U2OS cell lines were generated and obtained from Dr. Geoffrey Wahl, 
The Salk Institute for Biological Studies (La Jolla, California); U2OS FK2 cells were obtained 
from Dr. Xiaolin Nan, Oregon Health and Science University (Portland, Oregon); TBR2 cells were 
obtained from Dr. Sandra Orsulic, Cedars-Sinai  (Los Angeles, California) and all inducible 
sublines were generated in our laboratory. 
NIH3T3 and TBR2 cells were routinely grown in Dulbecco’s modified minimal essential medium 
(Cellgrow, VA) supplemented with 2 mM L-glutamine, nonessential amino acids, 100 U of 
penicillin, 100 µg of streptomycin, 1% sodium pyruvate and 10% fetal bovine serum (FBS). 
MCF10a cells were routinely grown in Dulbecco’s modified minimal essential medium: nutrient 
mixture-F12 supplemented with 5% FBS, 20 ng/mL EGF (Peprotech), 0.5 mg/mL Hydrocortisone 
(Sigma H-0888), 100 ng/mL Cholera Toxin (Sigma C-8052), 10 µg/mL insulin (Sigma I-1882), 
and 100 U of penicillin, 100 µg of streptomycin. 
AsPc-1, Panc-1, MiaPaca-2, H358, H441, TKOOV10, ID8, IG10, Hey-A8 and OVCAR8 cells 
were routinely grown in RPMI medium supplemented with 2 mM L-glutamine, nonessential amino 
acids, 100 U of penicillin, 100 µg of streptomycin and 10% FBS. 
Capan2 and SKOv3 cells were routinely grown in McCoy’s 5A medium supplemented with 2 mM 
L-glutamine, nonessential amino acids, 100 U of penicillin, 100 µg of streptomycin and 10% FBS. 
AsPc-1, Capan2, SKOv3, Hey-A8 and OVCAR8 inducible cell lines were maintained as 
previously specified using tetracycline free FBS (tet-FBS) and G418 to maintain clonal selections. 
DIRAS1, DIRAS2, or DIRAS3 expression was induced by adding 0.1 µg/mL doxycycline (Dox). 
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ReBiL-U2OS cell lines were routinely grown in Dulbecco’s modified minimal essential medium: 
nutrient mixture-F12 supplemented with 10% tet- FBS, 400 µg/mL G418, 10 µg/mL ciprofloxacin, 
5 ng/mL doxycycline, and 2-3 µg/mL blasticidin. Gene expression was induced by adding 0.01 
µg/mL doxycycline (Dox). 
U2OS FK2 cells were routinely grown in Dulbecco’s modified minimal essential medium: nutrient 
mixture-F12 supplemented with 10% tet-FBS, 10 µg/mL ciprofloxacin. Gene expression was 
induced by adding 0.01 µg/mL doxycycline (Dox). 
All cells were maintained at 37°C in a humidified atmosphere of 5% CO2 and routinely checked 
for Mycoplasma contamination. Cell line fingerprinting was performed to confirm identity of each 
line.  
OVCAR8-inducible Atg5-/- cells and a corresponding double nickase control were generated 
by transfecting OVCAR8-DIRAS1 or OVCAR8-DIRAS2 ovarian cancer cells with Atg5 crispr 
plasmid or a control plasmid for 48 hours prior to sorting for GFP positive cells. A pooled 
population of sorted cells were expanded and then subjected to an enrichment sort to obtain the 
cells with the greatest GFP-signal.  
Table 2.1 List of Reagents 
Reagent Description Company Catalog 
Lot 
Number 
0.05% Trypsin-EDTA Corning 25-052-CI  
0.25% Trypsin-EDTA Corning 25-053-CI  
0.5 M EDTA Gibco 15575-038  
1.0 M Tris HCl pH 7.0 (adjusted to 
6.8) 
TekNOVA T1070  
1.5 M Tris HCl pH 8.8 TekNOVA T1588  
10% SDS Invitrogen 24730-020  
10X TAE Buffer Ambion AM 9869  
10X Tris Buffered Saline RPI T60075-4000.0  
10X Tris/Glycine Buffer BioRad 161-0771  
10X Tris/Glycine/SDS Buffer BioRad 161-0772  
20X TBS-Tween pH 7.4 USB 77500  
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Reagent Description Company Catalog 
Lot 
Number 
2-mercaptoethanol Sigma Aldrich M6250-10ML  
30% Acrylamide BioRad 161-0156  
4+ Biotinylated Goat anti-Mouse IgG Biocare Medical GM601H 111915 
4+ Biotinylated Goat anti-Rabbit IgG Biocare Medical GR602H 71415 
4+ Streptavidin HRP Biocare Medical HP604H 90315 
488 Goat Anti-Mouse Life Technologies A11017  
488 Goat Anti-Rabbit Life Technologies A11008  
594 Goat Anti-Mouse Life Technologies A11020  
594 Goat Anti-Rabbit Life Technologies A11037  
5X siRNA Buffer Thermo Scientific 
B-002000-UB-
1000 
 
Acetic Acid - Glacial Fisher Scientific BP 24015-212  
Agar USB 1097 100GM  
All-In-One Mouse Tail Lysis Allele Biotechnology 
ABP-PP-
MT01500 
 
Annexin V 488 Invitrogen A 13201  
Annexin V-FITC Apoptosis Kit Life Technologies V13242  
Avidin Biocare Medical AB972H-A 62515 
BCA Protein Assay Thermo Scientific 23223, 23224  
Betazoid DAB Chromogen Biocare Medical BDB2004L 92016 
Biotin Biocare Medical AB972H-B 20816 
Bovine Serum Albumin Sigma-Aldrich A7906-500g  
Brilliant Blue Sigma-Aldrich B7920-50G  
BSA - Albumin Standard Thermo Scientific 23209  
CAPS Sigma-Aldrich C2632-1KG  
Cat-Hematoxylin Biocare Medical CATHE-M  
Chamber slides - Regular 4 well/ 2 
well 
Labtek 154526/154461  
Chloroform Mallinckrodt 4432  
Chloroquine Sigma Aldrich C6628-100.0  
Cholera Toxin (1mg/mL) Sigma Aldrich C-8052  
Ciprofloxacin Chem-Impex 02884  
Coomassie (BioSafe) BioRad 161-0786  
Dharmafect 1 Dharmacon T-2001-03  
Dharmafect 4 Dharmacon T-2004-03  
DMEM Corning 15-17-CV  
DMEM/F12 Corning 10-090-CV  
Doxycycline (1mg/mL) RPI D43020-100.0  
D-Sucrose Fisher Scientific BP 220-10  
ECL Perkin Elmer Perkin Elmer NEL 104001  
EGF (100 µg/mL) Peprotech 500-P45  
Ethanol 200 Proof Decon Laboratory 2701  
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Reagent Description Company Catalog 
Lot 
Number 
Fetal Bovine Serum Sigma-Aldrich F0926 15C487 
G418 Thermo Scientific 11811031 6716010 
Glycerol Fisher Scientific BP 229-1  
Hydrocortisone (1 mg/mL) Sigma Aldrich H-0888  
Insulin (10 mg/mL) Sigma Aldrich I1882  
iScript cDNA synthesis kit BioRad 170-8897  
iTaq Universal SYBR Green PCR 
Mix 
BioRad 172-5151  
LB Broth Sigma-Aldrich L-7275-500Tab  
L-Glutamine Corning 25-005-CV  
McCoys Corning 10-050-CV  
Megatran 1.0 Origene TT 200003  
Methanol Fisher Scientific BP 1105-4  
Mouse IgG Santa Cruz SC-2025  
Nuclear Fast Red Sigma Aldrich N3020-100 mL  
Nuclear/Cyto Extraction Thermo Scientific 78835  
OPTIMEM Gibco 31985-070  
Palbociclib PD: 0332991 Selleckchem 51116 07 
PBS without Ca2+ and Mg2+ Corning 21-040-CV  
Penicillin/Streptomycin Corning 30-002-CI  
PhosphoSTOP Roche 04 906 837 001  
Protein A/G Magnetic Beads Thermo Scientific 88803  
Puromycin (2.5 mg/mL) Sigma Aldrich P8833-1000  
QIA quick PCR Purification Kit Qiagen 28106  
Rabbit IgG Santa Cruz SC-2027  
Ras Activation Assay Cell Biolabs STA-400-H/K/  
Restore Plus Stripping Buffer Thermo Scientific 46430  
RPMI Corning 15-040-CV  
SDS-PAGE Ladder "Page Ruler 
Plus" 
Fisher Scientific 26619  
SDS-PAGE Ladder "Page Ruler" Fisher Scientific 26616  
Senescence SA. βgal  staining kit Sigma-Aldrich C50030-IKT  
Tag PCR Master Mix Qiagen 201445 148027375 
TEMED BioRad 161-0801  
tet-FBS Clontech 631106 A13020 
Trichloroacetic Acid RICCA 8693-16  
Trizol Ambion 15596018  
Trypan Blue Corning 25-900-CI  
Ultra-Pure Agarose Invitrogen 15510-027  
Xylene Fisher Scientific X3P-1GAL  
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Table 2.2 List of Antibodies 
Antibody 
Description 
Host Company Catalog Dilution Application 
488 Goat Anti-
Mouse 
G 
Life 
Technologies 
A11017 1:250 IF 
488 Goat Anti-
Rabbit 
G 
Life 
Technologies 
 1:250 IF 
594 Goat Anti-
Mouse 
G 
Life 
Technologies 
A11020 1:250 IF 
594 Goat Anti-
Rabbit 
G 
Life 
Technologies 
 1:250 IF 
Actinin R CST 6487 1:5,000 WB 
AKT M Santa Cruz SC-514302 1:1000 WB 
Anti-HA Tag M CST 2362 1:2000 WB, IP 
Anti-HA Tag M Sigma 068K4806 1:3000 WB, IP 
Atg 5 R CST 26305 1:1000 WB 
Atg 7 R CST 85585 1:1000 WB 
B-Actin R CST 4910L 1:10,000 WB 
Beclin1 R CST 3738S 1:1000 WB 
Cleaved-
Caspase3 
R Millipore 04-439 1:1000 WB 
DIRAS1 #13A M 
Bast 
Laboratory 
N/A 1:2000 WB, IF, IP 
DIRAS1 #64 M 
Bast 
Laboratory 
N/A 
1:3000 and 
1:1000 
WB, IHC, 
IF, IP 
DIRAS2 M Origene TA 809398 
1:15,000 
and 
1:10,000 
WB, IHC, 
IF, IP 
DIRAS3 15E11 M 
Bast 
Laboratory 
N/A 1:5000 WB 
DIRAS3 1D8 M 
Bast 
Laboratory 
N/A 
1:400 - 
1:5000 
WB, IHC, 
IF, IP 
Flag M2 M Sigma F316S 1:3000 WB 
FOX03a R CST 12829S 1:1000 WB, IF 
Goat Anti-Mouse G 
Fisher 
Scientific 
31439 1:10,000 WB 
Goat Anti-Rabbit G 
Fisher 
Scientific 
31463 1:10,000 WB 
His-Tag R CST 2366 1:1000 WB 
H-Ras R Cell Biolabs 240007 1:1000 WB 
Kras M 
Sigma and 
Invitrogen 
PAS-44339 1:1000 WB, IF 
K-Ras Abcam R Abcam 172949 1:1000 WB, IF 
LC3 R CST 2775 S 1:1000 WB, IF 
LC3 BXP R CST 3868S 1:700 IHC 
mTOR R CST 2972 1:1000 WB 
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Antibody 
Description 
Host Company Catalog Dilution Application 
P62/WQSTM1 R MBL PM045 1:10,000 WB 
Pan-Ras M Cell Biolabs 240002 1:1000 WB 
PARP M Millipore MAB3192 1:1,000 WB 
Phospho-ERK R CST 43705 1:1000 WB 
Phospho-mTOR R CST 2971 1:1000 WB 
SOS-1 mAb R CST 12409S 1:1000 WB 
TFEB R CST 4240S 1:500 WB, IF 
α-Tubulin R CST 5335S 1:1,000 WB 
 
Plasmids 
pCMV-DIRAS3 Y2, pCMV-ΔNT DIRAS3, plasmids were constructed in our laboratory. pCMV-
DIRAS1 and pCMV-DIRAS2 mouse and human plasmids were purchased from Origene. H-Ras 
plasmid was purchased from Clontech (631924) and site directed mutagenesis was used to 
create the H-Ras G12V plasmid in our laboratory. K-Ras, K-Ras G12V, NT-K-RasG12V, 4AA-K-
RasG12V, 34-AAScramble-KRasG12V, and 4-AAScramble-K-RasG12V and the corresponding 
H-Ras constructs were custom synthesized by Blue Heron. DIRAS3 C226S and NT-H-RasG12V 
were constructed in our laboratory. Plasmids synthesized by Blue Heron were re-cloned into a 
pCMV promoter expression plasmid. Viral GFP-K-RasG12V was provided by Dr. John Hancock 
(McGovern Medical School UTHealth). ATG5-/- CRISPR/Cas9 knockout plasmid was purchased 
from Santa Cruz Biotechnology sc-416847 and the control double nickase sc-437281. HA-tagged 
AKT-CA or AKT-DN plasmids (Myr-HA-AKT1-DD or Myr-HA-AKT1[AAA], respectively were 
obtained from Dr. Gordon Mills (University of Texas MD Anderson Cancer Center). 
Primers used for cloning include (5’  3’): 
H-RasE153A Forward GTAGAAGGCATCCGCCACTCCCTGCCG 
 Reverse CGGCAGGGAGTGGCGGATGCCTTCTAC 
   
H-RasY157A Forward CTCACGCACCAACGTGGCGAAGGCATCCTCCACT 
 Reverse AGTGGAGGATGCCTTCGCCACGTTGGTGCGTGAG 
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H-RasR161A Forward GTGCTGCCGGATCTCAGCCACCAACGTGTAGAAG 
 Reverse CTTCTACACGTTGGTGGCTGAGATCCGGCAGCAC 
 
Purified Recombinant Protein 
 His-K-Ras (1-185) (ab96817), H-Ras (1-186) (ab93949), and H-RasG12V (2-186) 
(ab140571) were purchased from Abcam. Flag-K-Ras (1-188) and Flag-DIRAS2 (1-199) was 
purchased from Origene. 
K-Ras (1-189), DIRAS3 (1-226) and DIRAS1 (1-189) were purified from BL21DE3 cells 
in our laboratory using a BioRad NGC Chromatography System.  
Transformation Assay 
Transformation of NIH3T3 cells was performed following standard protocols. (Clark, Cox 
et al. 1995) Low passage NIH3T3 cells were plated in 60 mm dishes at a density of ~1.2 x 106 
cells/plate. Transfection of single plasmids (20 µg) or co-transfection of differing plasmids (10 µg 
each) were completed 24 hours post seeding using MegaTran 1.0 (Origene) following 
manufacturers protocol. 24 hours post transfection, cells were trypsinized and plated onto 60 mm 
dishes at a ratio of 1:4 and kept in DMEM supplemented with dexamethasone (Sigma) or G418 
to determine transfection efficiency for 14 days, with media changed every 3-4 days. Cells treated 
with DMEM supplemented with G418 media were stained by Coomassie blue and colonies were 
counted to ensure equal transfection efficiency. Those plates treated with DMEM supplemented 
with dexamethasone were examined microscopically for signs of contact-uninhibited growth and 
the appearance of morphologically transformed foci. Transformed foci were counted at 10x 
magnification as they appeared within two 10x10 mm areas per plate. The assay was performed 
three times with technical duplicates of each transfection group.   
Anchorage Independent Growth 
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MCF10a cells were transfected with single or double DNA plasmids using MegaTran 1.0 
according to the manufacturer’s protocol. Twenty four hours following transfection, MCF10a cells 
were trypsinized and resuspended in RPMI containing 10% FBS and 0.35% noble agar, and 
plated on top of a layer of RPMI containing 10% FBS and 0.5% noble agar in a 35-mm dish. 
Media without epidermal growth factor (EGF) supplement was changed every 3 days and 
colonies were allowed to grow until they reached more than 50 cells/colony (~2-3 weeks). 
Colonies were visualized and quantified microscopically. 
siRNA Transfection 
Cells were transfected with control or DIRAS family siRNAs (single and pooled oligos) 
using the Transfection #1 or #4 reagent (Dharmacon Research, #T-2001-01, #T-2004-01). 
Briefly, a mixture of siRNA (100 nM final concentration) and transfection reagents were incubated 
for 20 minutes at room temperature. This mixture was then added to cells and allowed to incubate 
for 48-72 hours before cells were harvested for analysis.  
Transient Transfection  
Transient transfection was performed using MegaTran 1.0 (Origene, #TT200005) 
according to the manufacturer’s protocol. For transfection of a 6-well plate, 3μg of DNA was 
combined with 9μL of transfection reagent in 250μL of OPTIMEM and allowed to incubate at 
room temperature for 10 minutes before being added to the cultured cells. 
Cell Proliferation Assay 
Cell proliferation was determined using clonogenic and sulforhodamine B (SRB) assays. 
Clonogenic assays were performed using inducible cell lines where 400-800 cells/well were 
cultured with or without Doxycycline for 72 hours, or following transient transfection and selection 
with G418. Cells were then allowed to grow in a clonogenic fashion for two weeks prior to staining 
and fixation with Coomassie blue. Clonogenic growth was quantified by manual analysis of 
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colonies containing at least 50 cells. SRB short-term viability assays were performed following 
siRNA knockdown or doxycycline induced expression. Cells were plated at specified cell 
densities and transfected with siRNA as described above, or treated with 0.1 µg/mL doxycycline. 
Seventy two hours following treatment cells were fixed with 30% TCA at 4°C for 1 hour, followed 
by washing. Cells were incubated with 0.4% SRB for 30 minutes at room temperature before 
being washed with 1% acetic acid. Tris base (pH=10.5) was used to solubilize the SRB dye prior 
to reading the plates with a microplate-reader (Tecan) at 510 nm. 
Cell Migration Assay 
 SKOv3 and Hey-A8 ovarian cancer cells were seeded at 0.3 x 106 cells/well in a 6-well 
plates. Twenty-four hours later, cells were transfected with pLoc-DIRAS1, DIRAS2, or DIRAS3 
DNA plasmids and an empty vector control. Twenty-four hours post transfection, cells were 
trypsinized and re-seeded at 1,000 cells/well into an Oris cell migration assay plate, which 
contained a mask as provided by the manufacturer to assess the basal migration towards the 
center of the well upon imaging. The cells were incubated for 24 hours to permit attachment to 
the outer annular region of the wells. The stopper, provided in the assay kit to create a circular 
area free from cellular attachment in the center of the well, was removed and the plates were 
assessed on an IN-Cell Analyzer HCA (GE Life Sciences). Re-assessment occurred every 4 
hours for a period of 20 hours. Analysis was performed by quantifying the GFP-positive cells 
which had migrated to the center of the well at each time point. Experiments were performed in 
triplicate on three separate occasions.  
Ras activity Raf-RBD Pull-down Assay 
 H-Ras and K-Ras specific activity assays were purchased from CellBioLabs (STA-400-
K and STA-400-H) and performed following the manufacturer’s protocol. NIH3T3 cells were 
plated in 100 mm dishes at ~80% confluence. Twenty-four hours post seeding, cells were 
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transfected with 10 µg of DNA using MegaTran 1.0 (Origene) following the manufacturer’s 
protocol. 24 hours post transfection, cells were lysed as suggested following the CellBioLabs 
protocol and the assay was carried out according to the manufacturer’s protocol. 
Immunoprecitation and Immunoblotting 
 Treated cells were incubated for 30 minutes on ice in lysis buffer (50 mM Hepes, pH 7.0, 
150 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 10 mM NaF, 10 mM sodium pyrophosphate, 10% 
glycerol, 1% Triton X-100) plus protease and phosphatase inhibitors (1 mM PMSF, 10 µg/mL 
leupeptin, 10 µg/mL aprotinin and 1 mM Na3VO4) before being scraped and the lysate centrifuged 
at 17,000 x g for 20 minutes at 4°C. The protein concentration was assessed using a 
bicinchoninic acid (BCA) protein assay (ThermoScientific, Waltham, MA). Lysates (0.8-1.5 mg 
protein) were diluted with lysis buffer to a final volume of 1 mL. Immune complexes were 
incubated overnight with 2µg of the specified antibody or immunoglobulin control at 4°C with 
gentle agitation. Immune complexes were precipitated with protein A/G-magnetic beads for 1 
hour, and washed three times with IP wash buffer for 5 minutes each wash followed by two 
washes in PBS for 5 minutes each wash. Immunoprecipitated proteins were separated by SDS-
PAGE and transferred to PVDF membranes. Immunoblot analysis was performed with the 
indicated antibodies and visualized with an ECL enhanced chemiluminescence detection kit (GE 
Healthcare). Band intensity from western blots was quantified using the ImageJ program 
(Ferreira and Rasband, 2011).  
Peptide Array Analysis  
Peptide arrays were made using the MultiPep RS robot (Intavis, Bergisch Gladbach, 
Germany) according to the SPOT synthesis technique described by Frank et al. (Frank 2002) 
Arrays were developed by soaking membranes in 100% methanol for 10 minutes at room 
temperature followed by washing with PBS three times for 10 minutes each. Membranes were 
then blocked overnight at 4°C in 5% BSA/PBS. Recombinant proteins were added to the 
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membrane at a final concentration of 1 µg/mL in 1% BSA/PBS and shaken gently at room 
temperature for 2 hours. Membranes were washed three times for 10 minutes with 1% BSA/PBS 
prior to the addition of primary antibody diluted in wash buffer and incubation for 1 hour at room 
temperature. The membrane was washed 3x for 10 minutes and a diluted secondary antibody 
(1:10,000) was added for 45 minutes at room temperature, with gentle shaking. The membrane 
was washed 3x with wash buffer for 10 minutes, then followed with 3 washes with PBS-T for 10 
minutes. Membranes were developed with HRP substrates and exposed to X-Ray film.  
K-Ras4B Array (residues 1-189) 12-mer walk stepping by 3 amino acids. 
H-Ras Array (residues 1-186) 12-mer walk stepping by 3 amino acids. 
DIRAS3 Array (residues 1-229) 15-mer walk stepping by 3 amino acids. 
ReBiL Analysis of Protein-Protein Interactions 
Cells were seeded in 96-well or 384-well black wall, clear bottom plates and treated with 
doxycycline (1 µg/µL) to induce gene expression. 24-48 hours following gene expression the 
cells were washed briefly with 1X phosphate buffered saline (PBS) and luciferin was added. 
Plates were read for luciferase activity within 15 minutes using a Tecan plate reader. Each 
experiment was performed in triplicate on at least three separate occasions. Values for untreated 
cells were subtracted from the experimental values to reduce background.  
DUOLINK in situ Assay 
Duolink in situ PLA probes and Duolink in situ detection reagents were purchased from 
Sigma. K-Ras/DIRAS3 heterodimer formation was studied in Hey-A8-DIRAS3 ovarian cancer 
cells and AsPc-1-DIRAS3 pancreatic cancer cells. Procedures were performed following the 
manufacturer’s instructions. Briefly, cells were seeded on chamber slides, fixed, blocked and 
incubated with primary antibodies and then with secondary antibodies conjugated with 
oligonucleotides (PLA probe MINUS and PLA probe PLUS). Finally, cells were incubated 
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sequentially with ligation solution and amplification solution followed by analysis with 
fluorescence microscopy. 
Super-resolution fluorescence microscopy  
The custom multispectral super-resolution microscope (MSSRM) for multicolor 
superresolution imaging was constructed as described elsewhere (Huang et al. submitted). 
Briefly, the MSSRM is housed on a Nikon Ti-U inverted microscope frame equipped with two 
lasers emitting at 405 and 638 nm, respectively, an oil immersion objective (60x, numerical 
aperture 1.49), and an EM-CCD (Andor iXon+). Signals from the sample was collected through 
the objective and split between a positional channel and a spectral channel to enable 
simultaneous imaging of multiple fluorophores without having to use emission filters. The 
MSSRM setup achieves ~10 nm spectral resolution and hence is able to distinguish single Alexa 
Fluor 647 and CF660C molecules reliably as previously demonstrated. MSSRM imaging of 
fluorescently stained cells was performed in PBS buffer supplemented with 1% beta-
mercaptoethanol (βME), 5 µg/mL glucose oxidase (Sigma, G2133-50 kU), 0.4 µg/mL catalase 
(Sigma, C100-50 MG), and 10% glucose (w/v, Fisher Chemicals D16-500). The EM-CCD was 
operated in the in frame transfer mode at 15 ms per frame with a gain setting of 300. Acquisition 
of raw images was performed using the open source micromanager software suite (https://micro-
manager.org/) (Edelstein, Amodaj et al. 2010). Image analyses for extracting single-molecule 
localization, spectra were all performed with custom MatLab (Mathworks, MA) scripts as 
described previously (Nickerson, Huang et al. 2014). Coordinates of single molecules were 
grouped based on their peak emission wavelength. Images in each channel were rendered 
separately and recombined in Fiji (http://imagej.net/Fiji/) (Schindelin, Arganda-Carreras et al. 
2012) into a composite image.  
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EM Spatial Interaction and Cluster Analysis 
Using methods previously reported by Hancock et. al. (Prior, Muncke et al. 2003, Prior, 
Parton et al. 2003, Plowman, Muncke et al. 2005) we assessed the co-localization of K-RasG12V 
and DIRAS3 on the plasma membrane of HeyA8 ovarian cancer cells. HeyA8-DIRAS3 inducible 
cells were seeded at 1.0 x 105 cells/well in a six well plate onto gold EM grids with pioloform and 
poly-L-lysine coating. Expression of DIRAS3 was achieved by adding doxycycline to the media 
for 24 hours. Lentiviral K-RasG12V was then used to infect both doxycycline negative and 
positive samples for 18 hours prior to harvesting the EM grids and adherent cells for analysis. 
Briefly, the basolateral membrane was exposed and fixed using 4% paraformaldehyde (PFA) 
and 0.1% glutaraldehyde (GA). For univariate experiments, 4.5-nm gold nanoparticles pre-
coupled to GFP were used to immune-label GFP-Ras on the plasma membrane before 
embedding in uranyl acetate. Gold particle distribution was visualized by transmission electron 
microscopy (TEM) using JEOL JEM-1400 transmission EM. ImageJ was then used to assign x 
and y coordinates of gold particles in a 1-µm2 area on intact and featureless plasma membrane 
region. Ripley’s K-Function was used to calculate the gold particle distribution and extent of 
nanoclustering. (Plowman, Muncke et al. 2005) Bi-variate analysis of co-localization was 
performed in a similar fashion where the basolateral membrane was exposed and fixed with 4% 
PFA and 0.1% GA before sequential labeling with 6-nm gold nanoparticles pre-coupled to GFP 
followed by 2-nm gold nanoparticles pre-coupled to DIRAS3 (antibody ID8). Membranes were 
embedded in uranyl acetate and then imaged. (Prior, Parton et al. 2003) At least 15 plasma 
membrane sheets were imaged, analyzed and pooled for each condition.  
Measurement of mRNA expression  
RNA from pooled ovarian scrapings and ovarian cancer cell lines was extracted using 
RNeasy kit (Qiagen, #217004). cDNA was synthesized from 1 µg of RNA using the Superscript 
II First Strand Synthesis Kit (Invitrogen, #11904-018). SYBR green based quantitative PCR was 
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used to measure RNA levels. Relative expression was calculated by the 2-ΔΔCT method using 
glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) as the reference gene. The 
experiments were repeated at least three times, and samples were measured in triplicate.  
Primers included (5’  3’): 
hDIRAS1 Forward 102 GTTCTTGCAGCTGGCAC 
 Reverse 392 CTTGGAGATGGACAGGCG 
   
hDIRAS2 Forward 48 CTCTGAGCGGAGTTGTGTTC 
 Reverse 222 GATGTAGCTCTCCCGGAATG 
   
hDIRAS3 Forward GTACCTGCCGACCATTGAAAA 
 Reverse GGGTTTCCTTCTTGGTGACTG 
   
hSOS1  Forward GAGTGAATCTGCATGTCGGTT 
(Set 1) Reverse CTCTCATGTTTGGCTCCTACAC 
   
hSOS1  Forward ATGTATGTCGGCACTGGGTAG 
(Set 2) Reverse GACCTGGTCCATTGTCTCTTG 
   
mDIRAS1 Forward TTGCTGGTCATGTGTACTCTG 
 Reverse AATTCTAAGTCACCCTCATCTGG 
   
mDIRAS2 Forward CGGCTGGATTTTGATTCTTGG 
 Reverse GATGGCTTAGAGAATGGTCGAG 
   
 
OVCAR8-inducible cells were seeded in a 6-well plate at 1.5 x 105 cells/well, or following 
reverse transfection of siRNA at 1.0 x 105 cells/well. DIRAS1 or DIRAS2 expression was induced 
by adding DOX to the culture media for the indicated period of time. RNA was extracted with 
Trizol using the manufacturer’s protocol, and cDNA was synthesized from 1 µg of RNA using the 
Superscript II First Strand Synthesis Kit (Invitrogen, #11904-018). SYBR green based 
quantitative PCR was used to measure RNA levels. Relative expression was calculated by the 
2-ΔΔCT method using glyceraldehyde-3-phosphatase dehydrogenase (GAPDH) as the reference 
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gene. The experiments were repeated at least three times, and samples were measured in 
duplicate on each occasion.  
Primers included (5’  3’): 
ATG4 Forward CAGACCCCGTTGGATACTG 
 Reverse TCTTCCTTTGTGTCCACCTC 
   
ATG12 Forward CTGCTGGCGACACCAAGAAA 
 Reverse CGTGTTCGCTCTACTGCCC 
   
ULK1 Forward GGCAAGTTCGAGTTCTCCCG 
 Reverse CGACCTCCAAATCGTGCTTCT 
   
LC3 Forward 356F GAAGCAGCTTCCTGTTCTGG 
 Reverse 588R TCATCCCGAACGTCTCCTGG 
   
Rab7 Forward F2 AGCTGACTTTCTGACCAAGG 
 Reverse R2 TCGAGGTCAATCTTGTTT 
   
Gabarap Forward AGAAGAGCATCCGTTCGAGAA 
 Reverse CCAGGTCTCCTATCCGAGCTT 
   
Beclin1 Forward GAAGACAGAGCGATGGTAGTTC 
 Reverse CCTGGCGAGGAGTTTCAATAA 
   
Bnip3 Forward CAGGGCTCCTGGGTAGAACT 
 Reverse CTACTCCGTCCAGACTCATGC 
   
Rab11a Forward GAAAGCAAGAGCACCATTGG 
 Reverse ATCTCTCAGTTCTTTCAGCC 
   
LAMP1a Forward 1280F CAATTCCTACAAGTGCAACGC 
 Reverse 1428R GCATGCTGTTCTCGTCCA 
   
GAPDH Forward ATGGAATCCATCACCATCTT 
 Reverse CGCCCCACTTGATTTTGG 
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qRT-PCR 
 Total RNA was extracted using Trizol reagent (Invitrogen) and 100 ng of RNA was 
reversely transcribed and SYBR green-based real-time PCR reactions were conducted in 
triplicate with a Real-Time PCR system (BioRad) using iTaq Universal SYBR Green 1-Step Kit 
(BioRad, Cat: 1725150). Human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served 
as an endogenous control and reference gene. Data were analyzed using the 2-ΔΔCT method. 
Immunofluorescence Staining and Microscopy 
Immunofluorescence staining was performed using two well chamber slides, fixed with 
4% paraformaldehyde for 10 minutes prior to washing with PBS. Cells were permeabilized using 
0.05% Triton X in PBS for 10 minutes at room temperature. Cells were washed 3x with PBS for 
5 minutes each before being blocked with 0.5% BSA/PBS at room temperature for 1 hour. 
Primary antibodies were added at their specified dilution in 0.5% BSA/PBS and incubated 
overnight at 4°C. Cells were washed 3X with 0.5% BSA/PBS for 5 minutes each prior to the 
addition of secondary antibodies. Secondary antibodies were added at 1:250 dilution in 0.5% 
BSA/PBS and incubated at room temperature for 45 minutes. Cells were washed 3x with 0.5% 
BSA/PBS and DAPI staining at 1:10,000 dilution occurred at room temperature for 10 minutes. 
Slides were mounted, and imaged.  
Immunofluorescence and bright field microscopy were performed on an Olympus Ix71 
microscope equipped with a DP72 camera (BF) and a XM10 camera (IF) (Olympus, Center 
Valley, PA). Confocal microscopy was performed on an Olympus FV1000 Laser Confocal 
Microscope. 
Immunohistochemistry 
 Formalin-fixed, paraffin-embedded tissue microarrays were deparaffinized and 
rehydrated. Antigen retrieval was performed using a pressure cooker where the slides were 
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incubated in Tris-EDTA unmasking buffer for 10 minutes to retrieve latent epitopes, followed by 
sequential blocking steps with PeroxAbolish, avidin and biotin, and 5% BSA in PBS. The slides 
were incubated with a primary antibody or an isotype specific IgG control at the specified 
concentration listed above overnight at 4°C. The slides were washed and stained with a biotin-
labeled 4plus anti-species specific secondary antibody for 30 minutes at room temperature 
followed by 4plus streptavidin horseradish peroxidase (HRP) for 10 minutes. The slides were 
developed using a DAB chromogen kit and then counterstain with hematoxylin. Staining reagents 
were purchased from Biocare Medical. For tumor tissue microarrays, the slides were read 
separately by two investigators. Cases in which <20% of the core contained tumor were excluded 
from the analysis.  
Transmission Electron Microscopy 
 Cells were seeded in a 6-well plate and re-expression of DIRAS1, DIRAS2, and/or 
DIRAS3 was induced or transfected for a specified time period. After re-expression, samples 
were fixed with light Karnovsky’s fixative solution containing 3% glutaraldehyde plus 2% 
paraformaldehyde in 0.1 M cacodylate buffer at pH 7.3 and stored at 4°C. After fixation, samples 
were submitted to the MD Anderson electron microscopy core facility for processing. Briefly, cells 
were washed in 0.1 M cacodylate buffer and treated with 0.1% Millipore-filtered buffered tannic 
acid, post fixed with 1% buffered osmium tetroxide for 30 minutes, and stained with 1% Millipore-
filtered uranyl acetate. The samples were washed several time in water then dehydrated in 
increasing concentrations of ethanol, infiltrated, and embedded in LX-112 medium. The samples 
were polymerized in a 60°C oven for 2 days. Ultrathin sections were cut with a Leica Ultracut 
Microtome (Leica), stained with uranyl acetate and lead citrate in a Leica EM Stainer, and 
examined in a JEM 1010 transmission electron microscope (JEOL, USA, Inc.) at an accelerating 
voltage of 80 kV. Digital images were obtained using AMT Imaging System (Advanced 
Microscopy Techniques Corp). 
 
35 
    
 
AnnexinV and PI Staining for Apoptosis 
 Annexin V/PI staining was used to determine the percentage apoptotic cells following re-
expression of DIRAS1 or DIRAS2 as indicated. Cells were washed with PBS and trypsinized 
before centrifugation at 1000 rpm for 5 minutes. Cells were re-suspended in binding buffer and 
incubated for 20 minutes with fluorescence isothiocyanate (FITC) conjugated annexin V and 
propidium iodide (PI). Cells were analyzed on Beckman Coulter Gallios flow cytometer. 
Experiments were conducted in triplicate and repeated at least three times. 
Cell Cycle Analysis 
 The percentage of cells in different phases of the cell cycle was determined based on 
relative DNA content as determine by flow cytometry analysis. Inducible cells were treated with 
Doxycycline as indicated for the specific time to induce DIRAS1 or DIRAS2 expression. The cells 
were then detached by incubating with 0.05% trypsin-EDTA, washed with PBS and counted. Two 
million cells were fixed in 70% cold ethanol for 30 minutes. Cells were then pelleted by 
centrifugation at 1000 rpm for 5 minutes and washed in PBS two times. Cells were resuspended 
in PBS containing 1 µg/ml propidium iodine (PI) and RNaseA and incubated for 20 minutes at 
room temperature. Cells were analyzed on Beckman Coulter Gallios flow cytometer. 
Experiments were conducted in triplicate and repeated at least twice. 
Senescence SA-βGal Staining 
 DIRAS1 and DIRAS2 inducible ovarian cancer cells were grown in 6-well plates at an 
initial density of 15-3.0 x 103 cells per well. After 72 hours incubation with DOX to induce DIRAS1 
or DIRAS2 expression, cells were washed with PBS and fixed in 4% paraformaldehyde before 
staining with X-gal solution according to the manufacturer’s instructions (Senescence Cell 
Histochemical Staining kit, Sigma-Aldrich #CS0030). After cells were incubated in the staining 
solution for 4-16 hours at 37°C, β-galactosidase positive cells with blue precipitate were counted 
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and analyzed using bright field microscopy. Treatment with 5µM Palbociclib (Selleckchem, #PD-
0332991), a CDK4/6 inhibitor, was used as a positive control. 
Ovarian Cancer Cell Lines and Tissue Samples 
 Twelve human ovarian cancer cell lines (CaOv3, DOV13, HEY, OC316, OVCA 420, 
OVCA 432, OVCA 433, OVCAR3, OVCAR5, OVCAR8, SKOv3ip, and HeyA8) and 5 pools of 
normal human ovarian surface epithelial scrapings were grown at 37°C in an atmosphere of 5% 
CO2 and 95% air using the recommended cell culture medium for each cell line. Five pools of 
normal ovarian surface epithelium scrapings were obtained from the Division of Gynecologic 
Oncology at New York University using IRB approved protocols. All cancer and normal uterine 
specimens were snap frozen in liquid nitrogen and stored at -80°C. Normal ovarian epithelial 
scrapings were stored at -20°C in RNAlater® (Ambion, Foster City, CA). Protein and RNA 
extraction was performed as described elsewhere.  
Autophagy modulation 
 Cells were treated as described and chloroquine (5 µM) was added to inhibit lysosomal 
degradation for 18-24 hours prior to lysing the cells. To induce autophagy cells were rinsed briefly 
with PBS and the media was replaced with serum free media for 4-16 hours. 
Tissue Microarrays 
 Ovarian cancer tissue microarrays (TMAs) were prepared by the Pathology Core Facility 
that supports the M.D. Anderson SPORE in Ovarian Cancer. The microarrays contained 148 
distinct ovarian cancer specimens of which 122 were epithelial ovarian cancers where 
immunohistochemical staining could be interpreted. Protocols and informed consents to acquire 
and develop these arrays were approved by the respective Institutional Review Boards (IRB).  
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Mouse Xenografts and Measurement of Tumor Size 
 Five million DIRAS1-, DIRAS2-inducible cells and the parental SKOv3-IP and OVCAR8 
cell lines were injected intraperitoneally into six-week old female athymic nu/nu mice were 
purchased from Taconic Biosciences. Each group contained 8-10 mice. 2 mg/mL DOX in 5% 
sucrose or sucrose alone water starting the day of injection, and supplemented every two days 
throughout the duration of the study. The tumor mass (g) was determined 4-6 weeks post 
injection after euthanizing mice with CO2 and excising and pooling each intraperitoneal tumor 
nodule. All procedures were carried out according to an animal protocol approved by the IACUC 
of The University of Texas MD Anderson Cancer Center. 
Generation of Knockout Mouse Models 
 Validated sgRNA constructs were purchased from SageLabs, and prepared at a desired 
concentration of 2.5 ng/µL and Cas9 at 5 ng/µL to a total volume of 600 µL. Pro-nuclear injection 
of C57Bl6 embryos was performed by the MD Anderson Genetically Engineered Mouse facility. 
Backcrosses were performed two times and germline transmission was confirmed by genotyping. 
Genotyping was performed by dissolving a 1-2 mm tail sample in Allele-in-one tail direct lysis 
buffer (Allele Biotechnology, ABP-PP-MT01500) at 55°C overnight or until the tail was fully 
digested. Polymerase chain reaction (PCR) was performed on an optimized amount of direct 
lysis DNA (approximately 1:50 dilution) using Taq PCR Mastermix (Qiagen, #201443) and the 
following primers (5’  3’): 
DIRAS1 KO Forward  TGCCAGAACAGAGCAATGAC 
 Reverse  TCATCTTCGCTGAGGTTTCC 
   
DIRAS2 KO Forward TACATCCCGACTGTGGAAGA 
 Reverse GGTTGAGGAGTTCCTGAAAGAG 
 
PCR conditions were as follows: 94°C 5 min (1 cycle), 94°C 45 seconds followed by 55°C for 45 
seconds followed by 72°C for 45 seconds (30 cycles), 72°C for 5 min (1 cycle). PCR product was 
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purified with QIAquick PCR Purification kit (Qiagen, #28104) and then sent for Sanger 
sequencing using the MD Anderson Sequencing Core facility.  
Statistics 
All experiments were repeated independently at least two times and the data (bar graphs) 
expressed as mean ± s.d., unless noted otherwise. Statistical analysis was performed using 
Student’s t-test (two-sample assuming unequal variances). Survival analysis was performed 
using the Kaplan-Meier method. The criterion for statistical significance was taken as p<0.05 
(two-sided).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
DIRAS family members inhibit Ras-driven transformation and interact directly with 
Ras. 
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Somatic mutation of proteins belonging to the rat sarcoma (Ras) family was the first 
genetic alteration documented to drive human oncogenesis. Oncogenic mutations in K-Ras, N-
Ras, and H-Ras are found in nearly 30% of cancer cases, resulting in a constitutively active GTP-
bound state. (Prior, Lewis et al. 2012) Active, GTP-loaded Ras recruits effector proteins which 
perpetuate the signaling cascade resulting in cell proliferation and survival. (Karnoub and 
Weinberg 2008) Of the three major isoforms, K-Ras which has two splice variants 4A and 4B, is 
most commonly affected in cancer and it is estimated that 90% of pancreatic adenocarcinomas 
and ~60% of low grade ovarian cancers are driven by K-Ras mutations. (Singer, Oldt et al. 2003, 
Prior, Lewis et al. 2012) Despite decades of research, targeting constitutively active Ras has 
remained elusive. Recent reports suggest the role of Ras dimerization in this process, however 
no natural inhibitors of Ras dimerization/multimerization have been reported to date. 
(Muratcioglu, Chavan et al. 2015, Nan, Tamguney et al. 2015) Previous studies document the 
requirement of the membrane-anchoring domain for Ras dimerization/multimerization. (Nan, 
Tamguney et al. 2015) However, the specific mechanism by which this occurs has not been fully 
elucidated.  
DIRAS3 inhibits RasG12V–induced transformation of NIH3T3 murine fibroblasts and 
requires the N-terminal and CAAX domains of DIRAS3. Using a classical transformation assay 
to study the effects of mutant K-Ras on murine fibroblasts (NIH3T3), we observed that co-
transfection of constitutively active (G12V) mutant Ras constructs with wild-type DIRAS family 
members resulted in significant (p<0.01) inhibition of focus formation, compared to those co-
transfected with an empty vector control. Previous studies from the Bast lab has demonstrated 
that the N-terminal extension of DIRAS3 which distinguishes it from other members of the Ras 
superfamily, is critical for its suppressor function. Co-transfection of mutant K-Ras 
constructs (Figure 6A) with the N-terminal deleted construct of DIRAS3 (ΔNT DIRAS3) produced 
a similar number of foci in NIH3T3 murine fibroblasts, as did co-transfection with an empty vector 
control, underlying the  importance of the N-terminus in functional inhibition of Ras- induced 
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transformation. Additionally, a construct containing a single mutation in the CAAX membrane 
anchoring domain of DIRAS3 (C226S) was also unable to inhibit Ras transformation, 
demonstrating that localization of DIRAS3 to the membrane is important for functional inhibition 
of Ras. (Figure 6B)  
DIRAS3 inhibits RasG12V–induced transformation of MCF10a partially transformed 
breast epithelial cells 
and also requires the 
N-terminal and CAAX 
domains of DIRAS3. 
Importantly, the anti-
Ras role of DIRAS3 
was confirmed using 
MCF10a partially 
transformed breast 
epithelial cells. 
Similarly, co-
transfection of different 
DIRAS3 constructs with 
mutant Ras (G12V) 
significantly inhibit 
(p<0.01) clonogenic 
growth in soft agar 
(Figure 10D) after 2 
weeks following re-
expression of DIRAS3, 
but not ΔNT 
Figure 6. DIRAS3 inhibits Ras-induced malignant 
transformation of murine fibroblasts and Ras induced 
anchorage independent growth of breast epithelial cancer 
cells. A. Cartoon of constructs in pcDNA3.1 vector that were used 
for the following experiments. A-B. DIRAS3 inhibits K-Ras- (B) and 
H-Ras-induced (C) transformation of NIH3T3 cells. Cells were 
plated in 60 mm dishes and transfected with 10 µg of each DNA 
plasmid for 24 hours prior to being separated into dishes for focus 
formation and clonogenic selection by G418. Transformed foci were 
counted at 10x magnification as they appeared within two 10x10 
mm areas per plate. D-E. DIRAS3 inhibits anchorage independent 
growth of MCF10a breast epithelial cells transformed with K-Ras 
and H-Ras. Cells were cultured in 6-well plates and transfected with 
3 µg of each DNA plasmid for 24 hours prior to being re-seeded at 
a cell density of 1.0 x 105 in soft agar. Cells were grown for two 
weeks and colonies were quantified. The assay was performed 
three times with technical triplicates for each experiment. The 
columns indicate the mean, and the error bars indicate the S.D. 
(**p<0.01). 
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DIRAS3 and less significantly C226S. Similar results were obtained for H-Ras (Figure 6C and 
6E).  
DIRAS1 and DIRAS2 inhibit H-RasG12V-induced transformation of NIH3T3 murine 
fibroblasts. DIRAS1 and DIRAS2 were also able to inhibit Ras-induced transformation of NIH3T3 
mouse fibroblasts (Figure 7), exhibiting 
activity similar to DIRAS3. Co-transfection 
of mutant H-RasG12V with an empty 
vector control increased foci formation ~5 
fold compared to the empty vector alone, 
whereas co-transfection with the DIRAS 
family members inhibited the number of 
foci greater than 50%. 
 The N-terminal extensions of 
DIRAS1, 2, and 3 suppress the 
transforming activity of H-RasG12V. While 
DIRAS3 has a 34-amino acid N-terminal 
extension, DIRAS1 and DIRAS2 contain a 
4-amino acid N-terminal extension. To 
assess the effect of the N-termini directly, 
constructs were developed in which the N-terminal extension of DIRAS3 or DIRAS1/2 were fused 
directly to the N-terminus of mutant Ras. Compared to an empty vector control, or a 34- or 4-
amino acid scrambled control, the N-termini of the DIRAS family members were able to suppress 
Ras driven transformation. (Figure 8)  
 
 
Figure 7. DIRAS family members inhibit Ras-
induced transformation of NIH3T3 mouse 
fibroblasts. Cells were plated in 60 mm dishes 
and transfected with 10 µg of each DNA 
plasmid for 24 hours prior to being separated 
into dishes for foci formation and clonogenic 
selection by G418. Transformed foci were 
counted at 10x magnification as they appeared 
within two 10x10 mm areas per plate. The 
assay was performed in triplicate on three 
occasions. The columns indicate the mean, and 
the error bars indicate the S.D. (**p<0.01). 
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  DIRAS3 associates with K-Ras and requires the CAAX domain of DIRAS3. To delineate 
the role of DIRAS3 in Ras inhibition, we asked whether Ras associated with DIRAS3 as reported 
by Baljuls et. al.. (Baljuls, Beck et al. 2012) Using HeyA8-DIRAS3 ovarian cancer cell line, which 
harbors a K-Ras activating mutation and re-expression of DIRAS3 at near physiologic levels can 
be achieved by the addition of Doxycycline (DOX) in an inducible system, (Lu, Luo et al. 2008) 
we performed immunoprecipitation 
and observed that DIRAS3 and K-
Ras precipitated in the same 
complex (Figure 9A). Additionally, 
a DuoLink proximity ligation assay 
was performed, indicating close 
associates of DIRAS3 and K-Ras 
(Figure 9C). These results were 
confirmed using the AsPc-1-
DIRAS3 pancreatic cancer cell line 
engineered to express DIRAS3 
from a DOX-inducible promoter 
(Figure 9B and Figure 9D). Using 
purified recombinant protein, we 
observed a dose-dependent 
decrease in interaction between 
DIRAS3 and K-Ras, where the 
amount of DIRAS3 was held 
constant at 600 ng, and K-Ras was 
decreased from 600 ng to 30ng 
(Figure 9E). To quantify the  
Figure 8. DIRAS family N-termini inhibit Ras-
induced transformation of NIH3T3 mouse 
fibroblasts. A. Cartoon of constructs in pcDNA3.1 
Vector that were used for the following experiments. 
B. DIRAS3 or DIRAS1/2 N-termini were fused directly 
to the N-terminus of mutant H-Ras and transformation 
of NIH3T3 fibroblasts was assessed by focus 
formation. Cells were plated in 60 mm dishes and 
transfected with 10 µg of each DNA plasmid for 24 
hours prior to being separated into dishes for foci 
formation and clonogenic selection by G418. 
Transformed foci were counted at 10x magnification as 
they appeared within two 10x10 mm areas per plate. 
The assay was performed three times with technical 
triplicates for each experiment. The columns indicate 
the mean, and the error bars indicate the S.D. 
(**p<0.01). 
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protein was used for immunoprecipitation with a rabbit IgG control or anti-K-Ras antibody. 
Western blotting was performed and probed with anti-DIRAS3 antibody before stripping and 
probing with anti-K-Ras. D. A DuoLink in situ PLA assay was performed using AsPc-1-DIRAS3 
pancreatic cancer cells. Data were obtained from two independent experiments performed in 
duplicate. Columns indicate the mean, and the bars indicate the S.D. (**p<0.01). E. DIRAS3 
interacts with K-Ras in vitro. Purified recombinant DIRAS3 and K-Ras proteins were incubated 
together at different ratios to allow complex formation. The DIRAS3:K-Ras complexes that formed 
were immunoprecipitated with anti-K-Ras antibody and analyzed by western blotting. F. 
Luminescent signals were determined for several ReBiL cell lines to detect low affinity protein-
protein interactions and normalized to that of p53-MDM2. nLuc-cLuc was used as a negative 
control. K-Ras and K-RasG12D interaction was nearly 400% of p53-MDM2, and K-Ras DIRAS3 
or K-Ras NTD was slightly less. K-Ras and DIRAS3 C226S did not show a robust luminescence 
signal. Data were obtained from three independent experiments performed in triplicate. Columns 
indicate the mean, and the bars indicate the S.D. (**p<0.01).  
 
 
Figure 9. DIRAS3 interacts 
with K-Ras. A. Co-
immunoprecipitation of 
endogenous K-Ras in Hey-
A8-DIRAS3 ovarian cancer 
cells following induction of 
DIRAS3 expression by DOX. 
Cell lysate was collected and 
1.5 ug of protein lysate was 
used for 
immunoprecipitation with a 
rabbit IgG control or rabbit 
anti-K-Ras antibody. 
Western blotting was 
performed and probed with 
anti-DIRAS3 antibody before 
stripping and probing with 
anti-K-Ras. B. DIRAS3 and 
K-Ras formed heterodimers 
in Hey-A8-DIRAS3 cells. 
DIRAS3 and K-Ras 
complexes were analyzed 
with an in situ PLA assay. 
Data were obtained from two 
independent experiments 
performed in duplicate. 
Columns indicate the mean, 
and the bars indicate the 
S.D. (**p<0.01). C. AsPc-1-
DIRAS3 inducible cells were 
treated with or without DOX 
for 48 hours. Cell lysates 
were  collected and 1.5 µg of  
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relative binding affinity of DIRAS3 to K-Ras, we created cell lines using the Recombinase-
enhanced BiL system for detection of protein-protein interactions. (Li, Rodewald et al. 2014) 
U2OS, bone osteosarcoma cells with inducible expression of split luciferase complementing 
protein-protein interactions were generated. These lines included K-Ras-K-Ras, K-Ras-K-
RasG12D, K-Ras-DIRAS3, K-Ras- ΔNT DIRAS3, and K-Ras-DIRAS3 C226S. Using p53-Mdm2 
as a positive control, and nLuc-cLuc as a negative control, K-Ras-K-Ras and K-Ras-DIRAS3 
interactions were approximately 3-fold that of p53-MDM2. I found that the interaction between K-
Ras and DIRAS3 was not dependent upon the N-terminal extension of DIRAS3 as similar results 
to my immunoprecipitation studies were obtained using K-Ras- ΔNT DIRAS3; however, this 
interaction was dependent upon CAAX localization of DIRAS3 to the membrane as K-Ras-
DIRAS3 C266S no longer showed a robust interaction as compared to the wild-type DIRAS3 
construct (Figure 9F). 
This membrane dependent co-localization was observed by confocal microscopy using 
the U2OS K-Ras-DIRAS3 cancer cells (Figure 10A). Additionally, stochastic optical 
reconstruction microscopy (STORM) imaging performed at total internal reflection (TIRF) 
confirmed the interaction between DIRAS3 and K-Ras on the membrane (Figure 10B). Using 
methods previously reported by Hancock et. al. (Prior, Muncke et al. 2003, Prior, Parton et al. 
2003, Plowman, Muncke et al. 2005) we assessed the co-localization of K-RasG12V and 
DIRAS3 on the plasma membrane of Hey-A8-DIRAS3 ovarian cancer cells. Following infection 
of these cells with mGFP-K-RasG12V I harvested the plasma membrane and used anti-DIRAS3-
2nm-gold particles and anti-GFP-6nm-gold particles to assess the clustering and spatial 
orientation of DIRAS3 and K-Ras. K-function analysis revealed a significant interaction between 
DIRAS3 and K-Ras on the plasma membrane (Figure 10C-D).  
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DIRAS3 binds to the A5 helical domain of H-Ras and K-Ras. To identify the specific 
regions necessary for K-Ras-DIRAS3 interaction, I used peptide arrays (15-mer polypeptide 
sequences that span the entire length of the protein shifting by 1-3 amino acids at each spot) 
which identified the A5 helical domain of both H- and K-Ras as the primary region of DIRAS3 
Figure 10. DIRAS3 interacts with K-Ras at the plasma membrane. A. DIRAS3 co-localized 
with K-Ras in U2OS-701 cells treated with DOX for 24 hours to induce K-RasG12D and 
DIRAS3 gene expression. Immunofluorescence staining of DIRAS3 and K-Ras was analyzed 
by confocal microscopy. Scale bars: 30 µM. B. U2OS TR2 cells were treated with DOX for 24 
hours to induce K-Ras expression and simultaneously transfected with DIRAS3 pcDNA 
plasmid. STORM imaging at TIRF confirmed the interaction between DIRAS3 and K-Ras on 
the membrane. Scale bars: 2µm and 1µm for the higher magnification. DIRAS3 is labeled in 
red and K-Ras is labeled in green. C. TEM of DIRAS3- and K-Ras-labeled gold nanoparticles 
on the inner leaflet of the plasma membrane of Hey-A8-DIRAS3 ovarian cancer cells following 
induction of DIRAS3 by doxycycline for 24 hours. Scale bars: 100 nm and 20 nm for the higher 
magnification. DIRAS3 is labeled in red (2nm gold) and K-Ras is labeled in green (6nm gold). 
D. Bivariate K-function analysis of TEM documenting the extent of clustering and size of the 
clusters observed between K-Ras and DIRAS3 on the surface of the plasma membrane. 
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binding (Figure 11A). This 
sequence was further confirmed 
using a single amino acid shift 
peptide array spanning from amino 
acids 151 to 171 (Figure 11A). To 
confirm this interaction site, K-
RasG12V constructs harboring three 
point mutations (E153A, Y157A, and 
R161A) or deletion of the A5 helical 
domain (Δ153-161) were used for 
immunoprecipitation. The interaction 
between DIRAS3 and K-RasG12V 
was interrupted with mutagenesis to 
the A5 helical domain (Figure 11B). 
Using crystal structures of H-Ras 
and BRaf released July 2013 (4G0N) 
(Fetics, Guterres et al. 2015), we 
were able to model the binding of 
DIRAS3 to Ras and Raf 
demonstrating that DIRAS3 does not 
interfere with the Raf binding domain 
based on the peptide array 
predictions and confirming the 
possibility that all three proteins 
could act in a single complex (Figure 
11C). (Baljuls, Beck et al. 2012)  
Figure 11. DIRAS3 binds to Ras at the A5-helical 
domain. A. 15-mer peptide arrays generated for 
DIRAS3 and K-Ras were probed as described to 
determine possible sites of interaction. A confirmatory 
array of the A5 helical domain of K-Ras was also 
generated and probed with DIRAS3 recombinant 
protein. B. Immunoprecipitation of NIH3T3 cells co-
transfected with 10 µg of DIRAS3 and K-RasG12V 
constructs with mutations or deletion of the A5 helical 
domain. Western blot analysis was completed. C. A 
model of DIRAS3, H-Ras and B-Raf was developed 
based on the interactions predicted by peptide array 
analysis. The crystal structure of DIRAS3 has not 
been solved but DIRAS3 33-229 was predicted based 
on the known crystal structures of the DIRAS family 
homologs, DIRAS1 and DIRAS2. Based on the 
peptide array analysis and the co-crystal of H-Ras and 
B-Raf, DIRAS3 would likely not disrupt Ras-Raf 
binding directly.  
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The binding pattern between full length DIRAS3 and ΔNT DIRAS3 were nearly identical 
for both H- and K-Ras (Figure 12A). Similarly, DIRAS1 and DIRAS2 also appear to bind to the 
C-terminus of K-Ras by peptide array analysis (Figure 12B). Interestingly, DIRAS2 has a more 
potent effect on growth inhibition and also has a larger extent of overlapping interaction with the 
A5 helical domain of K-Ras compared to DIRAS1. Using immunoprecipitation, I confirmed 
DIRAS1 and DIRAS2 are also found in the same complex as Ras (Figure 12C-D). 
 
 
 
 
 
 
 
 
Figure 12. DIRAS family members share similar binding domains on Ras. A. 15-mer 
peptide arrays generated for H-Ras were probed with either full length DIRAS3 or ΔNT 
DIRAS3 as described to determine possible sites of interaction. B. 15-mer peptide arrays 
generated for K-Ras4b were probed with either full length DIRAS1, DIRAS2, DIRAS3 or 
ΔNT DIRAS3 as described to determine possible sites of interaction. The A5 helical domain 
is denoted by a red box. C. Co-immunoprecipitation of endogenous K-Ras in OVCAR8-
DIRAS1 ovarian cancer cells following induction of DIRAS1 expression by doxycycline. Cell 
lysate was collected and 1.5 ug of lysate was used for immunoprecipitation with a mouse 
IgG control or anti-DIRAS1 antibody. Western blotting was performed and probed with anti-
K-Ras antibody before stripping and probing with anti-DIRAS1. D. Co-immunoprecipitation 
of endogenous K-Ras in OVCAR8-DIRAS2 ovarian cancer cells following induction of 
DIRAS2 expression by DOX. Lysate was collected and probed as described above.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
DIRAS3 inhibits Ras-driven cancer and downstream ERK signaling by disrupting Ras 
multimerization/clustering. 
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DIRAS3 inhibits growth of K-Ras dependent ovarian, pancreatic, and lung cancer cell 
lines. Activating mutations in Ras promote increased PI3K and Ras/MAPK signaling cascades 
which are often denoted by increased p-AKT and p-ERK protein expression and promote 
increased cell proliferation. Previous studies demonstrated that re-expression of DIRAS3 at 
physiologic levels in 
ovarian cancer cell lines 
can inhibit clonogenic 
growth and the 
Ras/MAPK signaling 
pathway resulting in 
decreased p-ERK. (Lu, 
Luo et al. 2008) To 
examine the role of 
DIRAS3 in the 
regulation of K-Ras 
dependent cancer cell 
lines, I first tested the 
ability of several 
pancreatic and ovarian 
cancer cell lines, with a 
known activating K-Ras 
mutation, to grow 
following knockdown of 
K-Ras using four 
different small 
interfering RNAs 
Figure 13. Some ovarian, pancreatic and lung cancer cell lines 
with activating Ras mutations are dependent upon Ras for 
survival. A. Knockdown of K-Ras by siRNA inhibits growth of Hey-
A8 and AsPc-1 cancer cells. Reverse transfection (2,000 cells per 
well) of 4 different K-Ras siRNAs or a pooled mixture was a 
performed in a 96-well plate. Cells were then incubated for 72 
hours before fixation and staining by sulforhodamine B for cell 
viability. B. Knockdown of K-Ras by siRNA inhibits growth of H358, 
H441 (lung), Panc-1 and MiaPaca2 (pancreatic) cancer cells. 
Reverse transfection (2,000 cells per well) of pooled K-Ras siRNA 
was a performed in a 96-well plate. Cells were then incubated for 
72 hours before fixation and staining by sulforhodamine B for cell 
viability. Data were obtained from three independent experiments. 
K-Ras protein levels were measured by western blot analysis. The 
columns indicate the mean, and the bars indicate the S.D. 
(**p<0.01).   
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(siRNAs). Knockdown of K-Ras in AsPc-1 pancreatic cancer cells and HeyA8 high grade serous 
ovarian cancer cells significantly impaired cell viability in a 5 day sulforhodamine B (SRB) 
colorimetric assay of cytotoxicity, demonstrating the essential role of K-Ras in sustaining cell 
growth (Figure 13A). The same was true for Panc-1, MiaPaca2 (pancreatic), H358 and H441 
(lung) cancer cell lines (Figure 13B). Interestingly, decreases in proliferation appeared to directly 
correlate with the knockdown efficiency of K-Ras, showing a dose-dependent effect of K-Ras 
inhibition. This observation is clinically important as it demonstrates the level at which the 
Ras/MAPK pathway must be inhibited to suppress growth of K-Ras dependent cancers. Re-
expression of DIRAS3 using a tet-ON inducible system in AsPc-1-DIRAS3, Capan-2-DIRAS3, 
Hey-A8-DIRAS3 and OVCAR8-DIRAS3 inducible cancer cell lines inhibited clonogenic growth 
and downstream signaling driven by activated K-Ras (Figure 14 and Figure 16A-D). Re-
expression of DIRAS3 inhibited colony formation by approximately 50% at two weeks. Transient 
transfection of H358, H441 (lung), Panc-1 and MiaPaca2 (pancreatic), cancer cell lines 
Figure 14. Re-expression of DIRAS3 inhibits Ras-driven cancer viability. A-D. Re-
expression of DIRAS3 inhibits long-term clonogenic growth of Hey-A8-DIRAS3 (A), OVCAR8-
DIRAS3 (B), AsPc-1-DIRAS3 (C) and Capan-2-DIRAS3 (D) ovarian and pancreatic cancer 
cells. Cells were seeded, in triplicate in a 6-well plate with or without DOX for 2 weeks. 
Colonies were stained with Coomassie blue (left) and counted (right). Data were obtained 
from at least three independent experiments performed in triplicate. Columns indicate the 
mean, and the bars indicate the S.D. (**p<0.01). 
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demonstrated similar long term growth inhibition and decreased MAPK signaling, while 
transfection of ΔNT DIRAS3 did not have the same effect (Figure 15). These results are in line 
with previously published data from the Bast laboratory, documenting the role of the N-terminus 
to inhibit long-term clonogenic growth of ovarian cancer cells. (Luo, Fang et al. 2003, Lu, Luo et 
al. 2008) Using the complete panel of eight K-Ras dependent cancer cell lines from the pancreas, 
ovary and lung, the effect of re-expressing DIRAS3 on downstream Ras signaling was assessed. 
The MAPK/ERK signaling cascade is characterized by extracellular stimulation (growth factors, 
chemokines, hormones, integrins, receptor tyrosine kinases) which results in a series of 
sequential phosphorylation steps resulting in regulation of cytoplasmic proteins or transcription 
factors, based on the stimuli and effector bound to Ras. Once activated, GTP-bound Ras can 
recruit RAF to the plasma membrane where it can dimerize with a second Raf isoform before 
phosphorylating itself and then phosphorylating MAPK kinases/extracellular-signal-regulated 
kinases (MEK), which in turn phosphorylates and activates extracellular signal-regulated kinase 
(ERK). ERK phosphorylation is often assessed to determine downstream Ras pathway 
activation. In Hey-A8-DIRAS3, OVCAR8-DIRAS3 ovarian cancer cell lines and AsPc-1-DIRAS 
and Capan-2-DIRAS3 pancreatic cancer cell lines, re-expression of DIRAS3 was induced by the 
Figure 15. DIRAS3, but not ΔNT DIRAS3, inhibits long term clonogenic growth. A-D. 
Re-expression of DIRAS3 inhibits long-term clonogenic growth of H358 (A), H441 (B), Panc-
1 (C) and MiaPaca2 (D) lung and pancreatic cancer cells. Cells were transfected then re-
seeded, in triplicate in a 6-well plate with G418 selection for 2 weeks, allowing colonies of at 
least 50 cells to form. Colonies were stained with Coomassie blue (top) and counted 
(bottom). Data were obtained from at least three independent experiments performed in 
triplicate. Columns indicate the mean, and the bars indicate the S.D. (**p<0.01). 
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addition of DOX for 24 hours and western blot analysis of downstream ERK signaling was 
performed. A significant reduction was seen in p-ERK following re-expression of DIRAS3 for all 
four cell lines, where the 
significance of inhibition 
appeared to correlate with 
the amount of DIRAS3 
expression. (Figure 16A-D). 
Transient overexpression of 
DIRAS3 in H358 and H441 
lung cancer cell lines, and 
Panc-1 and MiaPaca2 
pancreatic cancer cell lines 
also demonstrated a 
significant decrease in p-
ERK compared to t-ERK for 
all four cell lines (Figure 
16E-H).  
Gene expression profiling allows mRNA expression levels to be measured for thousands 
of genes in a simultaneous fashion. This technique allows one to measure changes in expression 
levels following treatments, during development, or at a steady state across diseases, cell lines, 
tissues or organs. To gain a greater understanding of the expression profile of DIRAS3 across 
pancreatic cancer, we analyzed Affymetrix array data generated from a panel of pancreatic 
cancer cell lines, immortalized lines and normal pancreas controls in collaboration with Dr. Craig 
Logsdon. This analysis revealed that SU86.86 pancreatic cancer cell line had higher levels 
DIRAS3 mRNA expression (Figure 17). This data further demonstrated that DIRAS3 expression 
was likely downregulated in pancreatic cancer since the average relative expression of the 
Figure 16. DIRAS3 inhibits downstream Ras/MAPK 
signaling. A-D. Hey-A8-DIRAS3 cells were seeded at 0.3x106 
cells/well and treated with DOX for 24 hours before cell lysate 
was collected and western blot analysis performed. 
Densitometry was measured with ImageJ and experiments 
were performed at least three times. The ratio of p-ERK to t-
ERK was calculated and normalized to the DOX- control. 
Similar experiments were performed for OVCAR8-DIRAS3 
(B), AsPc-1-DIRAS3 (C) and Capan-2-DIRAS3 (D) inducible 
cell lines. E-H. Transient transfection of DIRAS3 or an empty 
vector control was performed for 24 hours and cell lysate was 
collected and western blot analysis performed. Densitometry 
was measured with ImageJ and experiments were performed 
at least three times. The ratio of p-ERK to t-ERK was 
calculated and normalized to the vector control. 
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cancer cell lines was approximately one-third that of normal pancreas. Endogenous expression 
of DIRAS3 was not observed by western blot analysis, however qRT-PCR revealed decreased 
mRNA expression of DIRAS3 upon siRNA transfection (Figure 18A-B). To test they hypothesis 
that DIRAS3 can inhibit pancreatic cancer cell growth, we used small interfering RNAs (siRNAs) 
against DIRAS3 and observed increased pERK and pAKT signaling (Figure 18C) and increased 
short-term viability (Figure 18D). The low levels of endogenous DIRAS3 expression likely 
account for the minimal increases in proliferation and signaling following siRNA depletion of 
DIRAS3 (Figure 18). 
DIRAS3, but not ΔNT DIRAS3, inhibits Ras multimerization. Recent studies have 
demonstrated a dimerization-dependent signaling mechanism of Ras. (Nan, Tamguney et al. 
2015) Using the ReBiL system, as described above, to detect Ras-Ras interactions we 
investigated the role of DIRAS3 or ΔNT DIRAS3 to inhibit Ras multimerization. Re-expression of 
DIRAS3, but not ΔNT DIRAS3, resulted in decreased luminescence as seen when K-Ras 
clusters are present (Figure 19A). These results were confirmed by immunoprecipitation of the 
K-Ras oligomers, where K-Ras was labeled with either an HA-tag or a Flag-tag and each was 
Figure 17. Relative mRNA expression of DIRAS3 across a panel of pancreatic cancer 
cell lines. Relative DIRAS3 mRNA expression was determined by affymetrix array of 
several pancreatic cancer cell lines as compared to normal pancreas or immortalized lines.  
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equally expressed using a 
bidirectional promoter 
following the addition of 
doxycycline. 
Immunoprecipitation of α-Flag 
K-Ras showed decrease co-
precipitation with HA-K-Ras 
when DIRAS3 was transiently 
introduced and then compared 
to an empty vector control or 
ΔNT DIRAS3. (Figure 19B) 
Similarly, DIRAS3 inhibited p-
ERK activation upon the 
addition of DOX expressing the 
oligomerizable K-Ras 
constructs, suggesting that 
activation of the signaling 
pathway is related to the multimerization/clustering (Figure 19B).  
DIRAS3, but not ΔNT DIRAS3, reduces K-RasG12V clustering on the plasma membrane 
and downstream p-ERK signaling. We used electron microscopy to examine the clustering of K-
RasG12V on the plasma membrane of Hey-A8-DIRAS3 ovarian cancer cells documents a 
striking difference in cluster size and extent of clustering with and without DIRAS3 expression. 
K-function analysis of the clustering documents that ovarian cancer cells without DIRAS3 
expression have a significantly larger extent of clustering (~ two Fold), as determined by 
integration of the K-Function univariate curve, and approximately two fold larger radius of the 
knockdown efficiency in SU86.86 pancreatic cancer cells, 
using OVCAR8-DIRAS3 as a positive control, documented 
undetectable protein levels. C. Reverse transfection of 
SU86.86 pancreatic cancer cells with pooled DIRAS3 siRNA 
was performed for 72 hours prior to harvesting the cells for 
western blot analysis. Blots were probed as indicated. 
Densitometry was measured with ImageJ and experiments 
were performed at least two times. The amount of p-ERK 
and p-AKT was calculated and normalized to the β-actin 
loading control. D. Reverse transfection (2,000 cells per 
well) of a pooled mixture of DIRAS3 siRNA was a performed 
in a 96-well plate. Cells were incubated for 72 hours before 
fixation and staining with sulforhodamine B to determine cell 
viability. Data were obtained from three independent 
experiments. The columns indicate the mean, and the bars 
indicate the S.D. (**p<0.01).   
Figure 18. Transient knockdown of 
DIRAS3 increases cell viability and 
p-ERK signaling of SU86.86 
pancreatic cancer cells. A. qPCR 
analysis of DIRAS3 mRNA of the 
SU86.86 cell line following siRNA 
knockdown of DIRAS3 at 72 hours. B. 
Western blot analysis of DIRAS3  
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clusters, which corresponds to increased p-ERK signaling by western blot analysis (Figure 19C-
E). As hypothesized, ΔNT DIRAS3 does not inhibit large K-RasG12V clustering on the plasma 
vector, DIRAS3 or ΔNT DIRAS3 plasmid DNA. DOX was added to induce K-Ras and K-
RasG12D for 24 hours prior to collecting the cell lysate. 1.5 mg of lysate was used for co-
immunoprecipitation with anti-Flag antibody or mouse IgG. Blots were probed as indicated. 
C. Cells lacking DIRAS3 form higher order clusters on the surface of the plasma membrane. 
TEM of GFP-K-RasG12V labeled gold nanoparticles on the inner leaflet of the plasma 
membrane of Hey-A8-DIRAS3 ovarian cancer cells following induction of DIRAS3 by DOX for 
24 hours. Univariate K-function analysis was performed to assess K-Ras cluster frequency 
and size. At least 15 plasma membrane sheets were imaged, analyzed and pooled for each 
condition. D. Analysis of the TEM data collected was used to determine the average cluster 
size (nm). Re-expression of DIRAS3 reduced the cluster size by approximately 6-fold, as 
compared to the Dox- sample or those expressing ΔNT DIRAS3. Columns indicate the mean, 
and the bars indicate the S.E. (**p<0.01). E. Lysate collected under the same experimental 
conditions used for TEM were assessed by western blot analysis and probed as indicated. 
Densitometry was measured with ImageJ and experiments were performed at least two times. 
The ratio of p-ERK to t-ERK was calculated and normalized to the DOX- control without K-
RasG12V viral transduction. 
Figure 19. DIRAS3 but not 
ΔNT DIRAS3 reduces Ras 
clustering and downstream 
signaling. DIRAS3 inhibits 
Ras multimerization. A. Cells 
were plated at 0.3 x 106 
cells/well in a 6-well plate and 
transfected with 3 µg of 
vector, DIRAS3 or ΔNT 
DIRAS3 plasmid DNA. 
Twenty-four hours post 
transfection, cells were re-
seeded into 96-well plates at 
a density of 5,000 cells/well. 
Doxycycline was added to 
induce the split luciferase K-
Ras constructs and 24 hours 
later the luminescent signals 
were determined for K-
Ras:K-RasG12D interaction. 
Data was obtained from three 
independent experiments 
performed in triplicate. 
Columns indicate the mean, 
and the bars indicate the S.D. 
(**p<0.01). B. DIRAS3 
reduced K-Ras co-
immunoprecipitation. U2OS 
605 cells were seeded in a 
60mm dish at 70% 
confluency prior to being 
transfected with 20 µg of 
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membrane nor does it inhibit p-ERK signaling. 
 DIRAS1 and DIRAS2 reduce Ras multimerization. Similarly, re-expression of DIRAS1 or 
DIRAS2 inhibited K-Ras multimerization 
dependent luminescence of the ReBil U2OS 
cancer cells (Figure 20). DOX was added to 
induce n_Luc_K-Ras and c_Luc_K-
RasG12D expression following transient 
transfection with DIRAS1, DIRAS2 or an 
empty vector control. Luminescence was 
measured as a surrogate for K-Ras 
multimerization, and upon normalization for 
cell viability we saw a statistically significant 
(p<0.01) decrease in luminescence 
(approximately 60% decrease) following re-
expression of DIRAS1 or DIRAS2.  
DIRAS3 reduces GTP binding by K-
Ras and Ras/Raf interaction. Despite 
previous efforts to determine if GTP activation 
of Ras enhances Ras clustering, there has 
not been clear evidence that GTP-binding is 
critical for multimerization. We have asked whether downstream Ras activation following 
dimerization, as determined by increased ERK signaling (Nan, Tamguney et al. 2015), might 
relate directly to GTP loading of Ras. To determine if decreased Ras dimerization by DIRAS3 
was due to decreased “active” Ras, we examined the levels of GTP-bound Ras following re-
expression of DIRAS3. Re-expression of DIRAS3 reduced GTP-bound Ras as determined by 
Ras binding domain (RBD) Raf immunoprecipitation. (Figure 21A-B) Using the ReBiL system to 
Figure 20. DIRAS1 and DIRAS2 reduce 
Ras multimerization. A. DIRAS1 and 
DIRAS2 inhibit Ras multimerization. Cells 
were plated at 0.3 x 106 cells/well in a 6-well 
plate and transfected with 3 µg of vector, 
DIRAS1 or DIRAS2 plasmid DNA. Twenty 
four hours post transfection, cells were re-
seeded into 96-well plates at a density of 
5,000 cells/well. DOX was added to induce 
the split luciferase K-Ras constructs and 24 
hours later the luminescent signals were 
determined for K-Ras:K-RasG12D 
interaction. Data was obtained from three 
independent experiments performed in 
triplicate. Columns indicate the mean, and 
the bars indicate the S.D. (**p<0.01). 
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detect K-RasG12D:BRaf interaction, I also measured the effect of the DIRAS family members to 
inhibit this downstream interaction in the signaling cascade (Figure 21C). I found that re-
expression of DIRAS1, DIRAS2 and DIRAS3 significantly reduced the K-RasG12D:B-Raf 
interaction, whereas ΔNT DIRAS3 (NTD) and DIRAS3 C226S constructs did not. These results 
were extended to determine if the N-terminus of DIRAS3 was responsible for this phenotype. 
Using DNA plasmids with the N-terminus of DIRAS3 (1-34 amino acids) added directly to the N-
terminus of mutant Ras I observed that the addition of the N-terminus reversed the mutant Ras 
function compared to H-RasG12V or a 34-amino acid N-terminus scrambled control. (Previously 
Figure 21. DIRAS3 inhibits GTP-bound Ras and subsequent Ras:Raf interaction. A. 
Assay schematic for Raf1 RBD agarose pull-down assay to determine levels of GTP-bound 
Ras. B. Hey-A8-DIRAS3 cells were plated at 70% confluency in a 100 mm dish and treated 
with or without doxycycline to induce DIRAS3 expression for 24 hrs. Cells were lysed and 
GTP-bound Ras was determined by Raf1 RBD (Ras binding domain) pull-down. 
Immunoblotting was performed and probed as indicated. C. ReBiL cells were plated at 0.3 x 
106 cells/well in a 6-well plate and transfected with 3 µg of Vector, DIRAS3, ΔNT DIRAS3 
(NTD), DIRAS3 C226S, DIRAS1 or DIRAS2 plasmid DNA. Twenty-four hours post 
transfection, cells were re-seeded into 96-well plates at a density of 5,000 cells/well. 
Doxycycline was added to induce the split luciferase constructs and 24 hours later the 
luminescent signals were determined for K-RasG12D:BRaf interaction. Data was obtained 
from three independent experiments performed in triplicate. Columns indicate the mean, and 
the bars indicate the S.D. (**p<0.01). 
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described in Figure 12) These constructs containing the N-terminus of DIRAS3 fused to mutant 
H-Ras resulted in decreased GTP-bound H-Ras, as well as downstream p-ERK and p-AKT 
signaling (Figure 22).  
Son of Sevenless 1 (Sos-1) 
is one of the first identified Ras 
guanine exchange factors, that 
helps catalyze the exchange of GDP 
to GTP upon activation of Ras. 
Named for its discovery in 
Drosophila melanogaster, it was 
found to operate downstream of the 
sevenless gene, which when 
mutated results in dysfunctional 
development of the fly’s eye when 
the seventh central photoreceptor 
fails to form. SOS1 and SOS2, the 
mammalian orthologues of Sos function downstream of many growth factor receptors. To 
investigate the importance of GTP binding in Ras multimerization, I tested the hypothesis that 
knocking down Sos-1, a critical guanosine exchange factor (GEF) to facilitate GTP binding to 
Ras, would inhibit GTP bound Ras and subsequently Ras multimerization. Knockdown of Sos-1 
by small interfering RNAs (siRNAs) significantly inhibits the GTP bound Ras (Figure 23A). 
Knockdown of Sos-1 also results in decreased multimerization of K-Ras and downstream 
signaling (Figure 23B-C). Taken together, this data suggests that activation of Ras could play a 
critical role in Ras multimerization/clustering. To determine if DIRAS3 was affecting Sos-1 to alter 
the GTP-bound state of Ras and could account for the significant decrease in Ras 
multimerization, I performed western blot analysis following re-expression of DIRAS3. Using 
Figure 22. DIRAS3 N-terminus inhibits GTP-bound 
Ras and downstream signaling. A. Cartoon of NT-H-
Ras constructs. B. NIH3T3 cells were plated at 70% 
confluency in 100 mm dishes and transfected with 15 µg 
of plasmid DNA before lysis and pull down by Raf1 RBD 
agarose beads to determine GTP-bound Ras. B-D. 
Immunoblotting was performed and probed as 
indicated. Experiments were performed at least three 
times and representative blots are shown.  
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AsPc-1-DIRAS inducible cells, re-expression of DIRAS3 was achieved by adding doxycycline to 
the culture media for 16-24 hours. Upon re-expression, DIRAS3 slightly reduced Sos-1 protein 
expression (Figure 24A-B), however this was not transcriptionally regulated (Figure 24C-D) as 
determined by qRT-PCR analysis with two independent sets of Sos-1 primers (Figure 24E). 
While this decrease in Sos-1 likely does not account for the more dramatic decrease in GTP-
bound Ras and Ras multimerization following re-expression of DIRAS3, this might provide a 
secondary mechanism by which DIRAS3 inhibits activated Ras signaling. Additionally, these data 
Figure 23. Ras multimerization and signaling depend on GTP-bound Ras.  A. ReBiL 
cells were plated at 70% confluency in 100 mm dishes and transfected with siRNA targeting 
Sos-1 or a non-targeting control before lysis and pull-down by Raf1 RBD agarose beads to 
determine GTP-bound Ras. Immunoblotting was performed and probed as indicated. B. 
Following siRNA knockdown, cells were re-seeded into 96-well plates at a density of 5,000 
cells/well. DOX was added to induce the split luciferase K-Ras constructs and 24 hours later 
the luminescent signals were determined for K-Ras:K-RasG12D interaction. Data was 
obtained from three independent experiments performed in triplicate. Columns indicate the 
mean, and the bars indicate the S.D. (**p<0.01). C. Immunoblotting to determine knockdown 
efficiency and ERK signaling was performed and probed as indicated. 
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suggest that DIRAS3 reduced GTP-bound Ras may be more related to the overall state of Ras, 
when bound to DIRAS3, rather than the effect of DIRAS3 on Ras GEFs or GAPs. 
Taken together my data suggest a membrane associated mechanism by which DIRAS3 
regulates Ras clustering and decreased binding with downstream activators of the signaling 
cascade resulting in decreased p-ERK signaling which is depicted in Figure 25.  
 
 
Figure 24. DIRAS3 inhibits Sos-1 protein expression but this is not transcriptionally 
regulated.  A. AsPc-1-DIRAS3 cells were seeded at a density of 0.3 x 106 cells/well and 
DIRAS3 expression was induced by the addition of doxycycline for 24 hours prior to lysis 
and immunoblotting as indicated. B. Sos-1 protein expression was quantified using Image J 
and normalized to the loading control. Data was obtained from three independent 
experiments performed in triplicate. Columns indicate the mean, and the bars indicate the 
S.D. (*p<0.05). C-D. qRT-PCR was performed with two independent Sos-1 primer sets to 
determine mRNA expression following re-expression of DIRAS3 in AsPc-1-DIRAS3 
pancreatic cancer cells. Columns indicate the mean, and the bars indicate the S.D. No 
significant change in mRNA expression was observed following re-expression of DIRAS3 at 
16 and 24 hrs. E. SYBR Green melt curve demonstrating the co-amplification of Sos-1, 
GAPDH, and DIRAS3 during the qRT-PCR.  
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Figure 25. Model of DIRAS3 inhibition of Ras clustering. Without DIRAS3 present in the 
cancer cells, Ras can form higher order clusters, resulting in increased Raf effector binding 
and subsequent downstream signaling activation. When DIRAS3 associates with Ras at the 
plasma membrane, the N-terminus regulates Ras multimerization, limiting the output of Ras 
effector signaling. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
DIRAS family members are conserved small GTPases with differential expression 
across multiple organs. 
 
 
 
 
 
 
 
 
 
64 
    
Throughout much of the last century our understanding of oncogenesis has deepened on 
many fronts, but the development of model systems, molecular and biochemical techniques, and 
large-scale data analysis in particular have been driving factors. From early work it was 
understood that oncogenesis occurs when either an oncogene is activated or through the loss of 
tumor suppressors, in which both alleles must be inactivated or silenced, allowing for 
uncontrolled cell division, invasion and metastasis.  
DIRAS3 (DIRAS family GTPase3, Distinct Subgroup of the Ras family member 3, also 
known as Aplasia Ras Homology I (ARHI) and Normal Ovarian Epithelial Yinhuna Yu 2 (NOEY2)) 
is a particularly interesting maternally imprinted tumor suppressor gene that is downregulated in 
a majority of ovarian cancers and several other tumor types. (Yu, Xu et al. 1999, Luo, Peng et 
al. 2001, Wang, Hoque et al. 2003, Rosen, Wang et al. 2004) As described above, DIRAS3 was 
identified as the most downregulated gene in high grade serous ovarian cancers compared to 
normal ovarian epithelial cells. More recent studies have focused on the molecular mechanisms 
whereby DIRAS3 regulates cell growth, motility, autophagy and tumor dormancy. Reports 
suggest that DIRAS3 is downregulated in ovarian cancer by several mechanisms including loss 
of heterozygosity (~40%), transcriptional regulation by E2F1/E2F4 or regulation by microRNAs 
(~10%), and hypermethylation of the paternal allele (~20%). (Lu, Luo et al. 2006, Lu, Luo et al. 
2006, Yu, Luo et al. 2006) 
Previous work from the Bast lab and others demonstrated the functional significance of 
DIRAS3 re-expression documenting the inhibition of growth, motility, and invasion, as well as the 
induction of autophagy and tumor dormancy. Much of this work has focused on the mechanisms 
by which DIRAS3 plays an essential role in the induction of autophagy by inhibiting the 
PI3K/AKT/mTOR signaling pathway, participating directly in the autophagy initiation complex by 
forming a heterodimer with Beclin1, and regulating the nuclear localization of the master 
autophagy-related transcription factor, FOXo3a. (Yu, Luo et al. 2006, Lu, Luo et al. 2008, Lu, 
Baquero et al. 2014, Lu, Yang et al. 2014) DIRAS3-induced autophagy can also sustain survival 
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of dormant ovarian cancer xenografts, and disruption of autophagy with chloroquine, a functional 
inhibitor, significantly delayed outgrowth of tumors following downregulation of DIRAS3. (Lu, Luo 
et al. 2008)  
The DIRAS family small GTPases are highly conserved members of the Ras-superfamily. 
The DIRAS family of small GTPases belong to the 
Ras superfamily of proteins. This family is made up 
of three family members known as DIRAS1 (Rig), 
DIRAS2 and DIRAS3 (ARHI, NOEY2). As with other 
small GTPases, this family of proteins are most 
notably characterized by their homology (40-60%) to 
Ras and Rap, and their ability to serve as a molecular 
switch binding GTP and GDP. DIRAS1 and DIRAS2 
have not been studied extensively and only few 
reports have indicated their function in tumor 
progression. (Ellis, Vos et al. 2002, Zhu, Fu et al. 
2013) Most recently, Bergom and colleagues 
described a tumor-suppressive role for DIRAS1, 
documenting that its interaction with SmgGDS, 
antagonizes the guanine nucleotide exchange factor 
and inhibits its binding to other small oncogenic 
GTPases. (Bergom, Hauser et al. 2016, Bergom, 
Hauser et al. 2016) These 22 kDa conserved 
GTPases have 50-60% homology with DIRAS3 
where the only major difference is the truncation of 
the N-terminal extension from 34-amino acids to 4-
amino acids (Figure 26). 
Figure 26. DIRAS family members 
are conserved GTPases with 
homology to Ras and Rap. A. 
Comparison of DIRAS family 
members with Ras and Rap. The 
four conserved GDP/GTP binding 
domains and the CAAX motif are 
underlined. Bold type indicates 
residues conserved in nearly all 
GTPases. Amino acids are 
designated according to the single 
letter code.  
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  DIRAS family expression is differentially expressed across tissues. DIRAS3 has been the 
most extensively studied of the three family members. To determine the expression of the DIRAS 
family members in normal tissue analysis of messenger RNA expression was performed in 
collaboration with Dr. Keith Baggerly and Shelley Herbrich across a panel of normal tissues in 
the Genotype-Tissue Expression (GTEx) database. GTEx was launched by the National 
Institutes of Health (NIH) in September 2010, and serves as a resource to study how inherited 
changes in gene expression can contribute to common human diseases. This database and 
tissue bank contains multiple human tissues from over 900 donors and has an accompanying 
online portal where genetic variation can be matched within their genomes. Using this data, I 
found that each DIRAS family member was differentially expressed across tissues, but, as 
hypothesized, those tissues known to have higher basal levels of autophagy (e.g. heart, brain) 
had relatively higher messenger RNA expression of DIRAS1, DIRAS2 and DIRAS3 (Figure 27).  
 
 
Figure 27. DIRAS family members are differentially expressed across tissues. RNAseq 
data obtained from the Genotype-Tissue Expression (GTEx) project was analyzed according 
to tissue site and relative expression of DIRAS1, DIRAS2 and DIRAS3 were plotted. 
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To determine if the messenger RNA expression levels correlated with protein expression, 
we performed immunohistochemical staining of normal organ tissue arrays. The arrays contained 
2-6 samples per tissue site, and included samples from 27 different organ sites. I found that 
DIRAS1 was expressed the least frequently of the DIRAS family members and that similar 
patterns of expression were observed when compared to the mRNA expression obtained from 
the GTEx analysis (Figure 28). All three family members were strongly expressed in adrenal 
gland, eye, kidney, pancreas and stomach. DIRAS2 and DIRAS3 were both highly expressed in 
cerebellum, cerebrum, hypophysis (pituitary gland), liver, parathyroid gland, prostate, small 
intestine, testis, thymus, and uterine cervix.  
 
DIRAS1 and DIRAS2 are downregulated in ovarian cancer. To determine the expression 
of DIRAS1 and DIRAS2 in ovarian cancer, immunohistochemical staining of tumor microarrays 
Figure 28. DIRAS family proteins are expressed differentially across multiple organs. 
Analysis of DIRAS family protein expression across multiple organ sites as determined by 
immunohistochemical staining analysis. 
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was performed. Of 123 cases, 67 cases did not express DIRAS1 (55%) and 16 cases did not 
express DIRAS2 (13%), and were scored 0. Those cases with definite, but low expression in the 
tumor, were scored as 1, whereas those with moderate expression were scored as 2. High 
expression was scored as 3, and this occurred in 9 cases for DIRAS1 (7%) and 15 cases for 
DIRAS2 (12%). Representative images of the scoring for each group are shown in Figure 29. 
Survival analysis revealed a significantly longer progression-free and overall survival for patients 
that had high (Score 3) DIRAS1 or DIRAS2 expression compared to those who did not have any 
expression (Score 0) (Figure 30).  
 
Figure 29. DIRAS1 and DIRAS2 immunohistochemical staining of ovarian cancer 
tissue microarrays. Normal ovaries and tumor tissue microarrays with 123 cases were 
analyzed using immunohistochemistry with anti-DIRAS1 and anti-DIRAS2 antibodies and 
scored 0 to 3. Examples from the tumor array representing the score 0 (no expression), 1 
(low expression), 2 (moderate expression) and 3 (high expression were shown with 10x 
magnification, and enlarged 40x magnification insets for each antibody. Bar represents 100 
um for 10x and 20 um for 40x. 
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The median overall survival for those patients who did not have any DIRAS1 expression 
was 31.4 months compared to 55.7 months for those with high expression. Likewise, patients 
whose tumors had high DIRAS2 expression has a median overall survival of 46.7 months 
compared to 29.4 months when no expression was present (Figure 30A-F). 
 
Figure 30. DIRAS family expression is a predictor of overall survival for ovarian cancer 
patients. A. The fraction of ovarian cancers with DIRAS1 expression. B. The correlation 
between disease free survival and overall survival by staining score of DIRAS1. Each circle 
represents one patient sample. C. The fraction of ovarian cancers with DIRAS2 expression. 
D. The correlation between disease free survival and overall survival by staining score of 
DIRAS1. Each circle represents one patient sample. E. Kaplan-Meier overall survival 
analysis of DIRAS1 expression by staining score. F. Kaplan-Meier overall survival analysis 
of DIRAS2 expression by staining score. 
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Western blot analysis of three normal ovarian epithelial scrapings, tumor lysate from 11 
patients with high grade serous ovarian cancer and 14 ovarian cancer cell lines was performed 
to assess expression of DIRAS1 and 
DIRAS2. Based on the average 
densitometry of the normal ovarian 
epithelial scrapings, I found that 
DIRAS1 was downregulated in 10 of 
11 patient tumor samples (91%) and 
12 of 14 ovarian cancer cell lines 
(93%) whereas DIRAS2 was 
downregulated in 8 of 11 patient 
tumor samples (73%) and 9 of 14 
ovarian cancer cell lines (64%) 
(Figure 31). 
Figure 31. DIRAS family expression is 
downregulated in ovarian cancers and cancer 
cell lines. Western blot analysis of three normal 
ovarian epithelial scrapings, tumor lysate from 11 
patients with high grade serous ovarian cancer 
and 14 ovarian cancer cell lines was performed to 
assess expression of DIRAS1 and DIRAS2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
DIRAS1 and DIRAS2 inhibit ovarian cancer cell growth by inducing autophagic cell 
death. 
 
 
 
 
 
 
 
 
 
 
 
72 
    
DIRAS3 (ARHI) is a known tumor suppressor of ovarian cancer, and has been shown to 
inhibit long term and short cell viability, which is dependent upon its N-terminal extension. 
Although DIRAS1 and DIRAS2 only have a 4-amino acid N-terminal extension compared to Ras, 
I sought out to determine if DIRAS1 or DIRAS2 would also have a tumor suppressive role. Using 
stable sublines of OVCAR8, SKOv3-IP and Hey-A8 ovarian cancer cell lines with Tet-on inducible 
expression of DIRAS1 or DIRAS2 as well as transient transfection of DIRAS1 or DIRAS2 I 
determined their effect on long term and short-term cell viability.  
DIRAS1 and DIRAS2 suppress growth of ovarian cancer cell lines. Induction of DIRAS1 
or DIRAS2 expression following incubation of each subline with 1 ng/mL DOX produced stable 
expression of each gene and long term and short term cell viability was measured. Re-expression 
of both DIRAS1 
and DIRAS2 
resulted in 
inhibited cancer 
cell clonogenic 
growth. Two 
subclones were 
used for each 
inducible subline 
to ensure the 
effect observed 
was not just 
selected for 
upon subcloning 
(Figure 32 and 
Figure 33).  
Figure 32. Re-expression of DIRAS1 or DIRAS2 inhibits long-term 
ovarian cancer clonogenic growth. A-B. Two distinct subclones of 
OVCAR8-DIRAS1 or OVCAR8-DIRAS2 cells were seeded at 400 
cells/well and doxycycline was used every 48 hours for 6 days to induce 
gene expression. Colonies were allowed to grow for 2 weeks and then 
stained with Coomassie blue. Percentage of growth inhibition was 
determined for three independent experiments all performed with triplicate 
samples. C-F. Similar experiments were carried out in SKOv3-IP-inducible 
lines and Hey-A8-inducible lines seeded at 800 and 600 cells per well, 
respectively. 
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Figure 33. Re-expression of DIRAS1 or DIRAS2 inhibits short-term cell viability. A-B. 
Two distinct subclones of OVCAR8-DIRAS1 or OVCAR8-DIRAS2 cells were seeded at 
1,000 cells/well in a 96-well format and doxycycline was added every 24 hours for a total of 
72 hrs. Plates were then fixed with 30%TCA Percentage of growth inhibition was 
determined for three independent experiments all performed with triplicate samples. C-F. 
Similar experiments were carried out in SKOv3-IP-inducible lines and Hey-A8-inducible 
lines seeded at 800 and 600 cells per well, respectively. 
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DIRAS1 and DIRAS2 inhibit human ovarian cancer xenograft growth. To determine whether 
growth inhibition was observed in vivo, 5 million OVCAR8- or SKOv3-IP-inducible cells, and their 
parental controls were injected intraperitoneally into 6-week old athymic nude mice. Doxycycline 
was added to the drinking 
water to induce DIRAS1 
or DIRAS2 gene 
expression, and tumor 
burden was assessed 4-6 
weeks post injection. In 
both cases re-expression 
of DIRAS1 or DIRAS2 
inhibited tumor burden 
and the parental cell lines 
were not affected by the 
addition of doxycycline to 
the drinking water (Figure 
34A-B). 
Neither DIRAS1 nor DIRAS2 induce apoptosis, cell cycle arrest or senescence. Using the 
previously described inducible ovarian cancer cell lines, we next sought to identify the 
mechanism(s) by which DIRAS1 and DIRAS2 might contribute to growth inhibition. Using 
cisplatin as a positive control, I measured Annexin V/Propidium Iodide (PI) staining to determine 
the percentage of apoptotic cells following re-expression of DIRAS1 and DIRAS2 over a time 
period of 72 hours, by flow cytometry. Neither DIRAS1 (Figure 35A) nor DIRAS2 (Figure 35C) 
upregulation produced significantly different levels of apoptosis judged by immunostaining for 
Annexin V/PI, but apoptosis was readily induced in the same three inducible cell lines by  
treatment with cisplatin. Western blot analysis of cleaved caspase 3 confirmed these results  
Figure 34. Re-expression of DIRAS1 and DIRAS2 inhibit 
growth of orthotopic ovarian cancer xenografts in vivo.  
DIRAS1 or DIRAS2 expression inhibits tumor growth in mouse 
orthotropic xenografts. Mice were injected intraperitoneally 
(i.p.) with five million OVCAR8-inducible (A), SKOv3-IP-
inducible cells (B) or the parental controls and were 
immediately fed with sucrose water with or without the addition 
of doxycycline for the duration of the experiment. Six weeks 
following the injection, the mice were sacrificed and the tumors 
were extracted upon necropsy. The tumor burden was 
determined by mass, and each dot represents a single mouse. 
Asterisk denotes significant difference (*p<0.05 or **p<0.01).  
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(Figure 35B and 35D). Cell cycle analysis was performed using flow cytometry of PI stained 
inducible ovarian cancer cells. While slight changes were observed no significant increases in 
Figure 35. Growth inhibition of ovarian cancer cells following re-expression 
of DIRAS family members is not due to apoptosis. A-D. OVCAR8-inducible, 
SKOv3-IP-inducible and Hey-A8-inducible ovarian cancer cell lines were treated 
with or without doxycycline for 24, 48, and 72 hours. An additional plate was 
treated with cisplatin (5-20 µM) for 72 hours and used as a positive control. Cells 
were stained with Annexin V/PI and analyzed by flow cytometry, or western blot 
analysis of cleaved caspase 3, no significant change was overserved in the level 
of apoptotic cells following re-expression of DIRAS1 or DIRAS2. Data was 
collected over three independent experiments with technical duplicates for each. 
Asterisk denotes significant difference (*p<0.05 or **p<0.01). 
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cell cycle arrest were noted across G 1, S, or G2/M for both DIRAS1 and DIRAS2 in the three 
inducible cell lines (Figure 36). These results suggest that cell cycle arrest is not the main 
Figure 36. Growth inhibition of ovarian cancer cell following re-expression of 
DIRAS family members is not due to cell cycle arrest. A-E. OVCAR8-inducible, 
SKOv3-IP-inducible and Hey-A8-inducible ovarian cancer cell lines were treated with or 
without doxycycline for 24, 48, and 72 hours. Cells were collected and stained with 
propidium iodide and analyzed for cell cycle using flow cytometry. No significant changes 
were observed in cell cycle at G0/G1, S, or G2/M phase. Data was collected over three 
independent experiments with technical duplicates for each. Asterisk denotes significant 
difference (*p<0.05 or **p<0.01). 
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 mechanism by which 
DIRAS1 or DIRAS2 inhibit 
ovarian cancer cell growth. 
Next I investigated the 
induction of cellular 
senescence by SA-β-Gal 
staining. Cellular senescence 
or cellular aging is a normal 
phenomenon where diploid 
cells cease to divide, adopting 
a permanent state of cell-cycle 
arrest. Senescence markers 
include lack of DNA replication 
(which cannot be 
distinguished from 
quiescence), or staining with 
the senescence-associated β-
galactosidase (SA-β-gal). 
Similarly, re-expression of 
DIRAS1 or DIRAS2 did not 
produce a significant increase 
in positively stained cells, but 
treatment with the CDK4/6 
inhibitor palbociclib did, 
providing a positive control 
(Figure 37). SA-β-Gal staining 
Figure 37. Growth inhibition of ovarian cancer cell 
following re-expression of DIRAS family members is not 
due to senescence. A-C. Senescence of OVCAR8-
inducible, SKOv3-IP-inducible and Hey-A8-inducible ovarian 
cancer cell lines was analyzed by SA-β-Gal staining 
following treatment with or without doxycycline for 72 hours. 
5µM palbociblib, a CDK4/6 inhibitor was used as a positive 
control. No significant increase in senescence was observed 
following re-expression of DIRAS1 or DIRAS2. Data was 
collected over three independent experiments with technical 
duplicates for each. Asterisk denotes significant difference 
(*p<0.05 or **p<0.01). 
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was extremely faint in the p53 null SKOv3 cell line, as would be predicted based on the role of 
p53 to activate this pathway.  
DIRAS1 and DIRAS2 induce autophagy. LC3-I conversion to its cleaved product LC3-II 
generated by ATG4, a cysteine protease, is a key process during the elongation and formation 
of the autophagosome membrane, and frequently used to document the induction of autophagy. 
(Asanuma, Tanida et al. 2003) Using the previously described OVCAR8-inducible, SKOv3-
Figure 38. Re-expression of DIRAS family members induce autophagy. OVCAR8-
inducible cells were treated with or without doxycycline for 18 hours with or without the 
presence of chloroquine (5 µM). A. Cell lysate was collected and western blot analysis was 
performed to examine the conversion of LC3 I to LC3 II, p62 levels, and expression of DIRAS1 
or DIRAS2. β-actin was used as a loading control. Upon re-expression of DIRAS1 or DIRAS2 
we observed decreased p62 levels and increased conversion to LC3 II, which was further 
enhanced by the addition of chloroquine. B-C. Immunofluorescence staining of DIRAS1 or 
DIRAS2 (green) and LC3B (red) was performed to document the formation of 
autophagosomes. Scale bar indicates 10 µm. D. TEM images of induced or control OVCAR8-
DIRAS1 or DIRAS2 cells. Red arrows indicate typical double-membrane autophagosomes. 
Scale bars: 5 µm and 5 nm for close up image. Data was collected over three independent 
experiments. Asterisk denotes significant difference (*p<0.05 or **p<0.01). 
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inducible and HeyA8-inducible sublines of ovarian cancer, I induced DIRAS1 or DIRAS2 
expression for 18-24 hours with the addition of doxycycline. Upon re-expression I observed an 
increased LC3-II to LC3-I ratio, that could be further enhanced by using chloroquine, a functional 
inhibitor of autophagy (Figure 38). The same was true in both SKOv3-inducible and Hey-A8-
inducible ovarian cancer cell lines (Figure 39). Using immunofluorescence I was able to confirm 
these results by staining for MAP-LC3B, where the formation of punctae demonstrate the 
Figure 39. Re-expression of DIRAS family members induces autophagy in SKOv3 
and HeyA8 ovarian cancer cells. SKOv3-IP-inducible and Hey-A8-inducible cells were 
treated with or without DOX for 24 hours with or without the presence of chloroquine (5 
µM). A-B. Cell lysate was collected and western blot analysis was performed to examine 
the conversion of LC3 I to LC3 II, p62 levels, and expression of DIRAS1 or DIRAS2. β-actin 
was used as a loading control. Upon re-expression of DIRAS1 or DIRAS2 we observed 
decreased p62 levels and increased conversion to LC3 II, which was further enhanced by 
the addition of chloroquine. C-D. TEM images of induced or control SKOv3-IP- or Hey-A8-
DIRAS1 or -DIRAS2 cells. White arrows indicate typical double-membranes 
autophagosomes. Scale bars: 5 µm and 5 nm for close up image. Data was collected over 
three independent experiments.  
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presence of autophagosomes and represents the accumulation of a membrane-bound form of 
LC3 on autophagic vesicles (Kabeya, Mizushima et al. 2000, Takahashi, Coppola et al. 2007) 
(Figure 38B-C). Interestingly, neither DIRAS1 nor DIRAS2 does co-localized with LC3B by 
immunofluorescence staining, differing from DIRAS3 in this regard. Transmission electron 
microscopy (TEM) is the gold standard for detection of autophagosome formation and the 
characteristic feature is the presence of intracellular contents that are enclosed by a double-
membrane vacuolar structure. TEM performed on OVCAR8-inducible, SKOv3-inducible and 
HeyA8-inducible cells with and without the re-expression of DIRAS1 or DIRAS2 confirmed my 
previously documented results and demonstrated autophagosomes, which contained multiple 
lamellae, intact cytoplasmic structures and residual digested materials (Figure 38D and Figure 
39C-D). Although basal autophagy and autophagosome formation was observed in the samples 
without DOX, there was a significant increase, not only in number but also size of the 
autophagosomes once DIRAS1 or DIRAS2 was re-expressed.  
Inhibition of autophagy by knockdown of Atg5 prevents DIRAS1 and DIRAS2 inhibition of 
ovarian cancer cell growth. Autophagy protein 5 (Atg5) is a well-characterized E3 ubiquitin ligase 
that is essential for the elongation of the autophagosome. Following activation by Atg7, Atg5 
forms a complex with ATG12 which is necessary for conjugation of phosphatidylethanolamine to 
LC3-I, allowing for cleavage to the LC3-II form. Using the CRISPR/Cas9 gene editing technique 
I developed Atg5 -/- cells and their paired controls for the OVCAR8-DIRAS1 and OVCAR8-
DIRAS2 inducible cell lines. Following development of these lines I determined if knockdown of 
Atg5 would inhibit DIRAS1 or DIRAS2-induced autophagy as determined by LC3 II conversion 
(Figure 40A-B). The growth inhibition observed following re-expression of DIRAS1 or DIRAS2 
was also dependent upon functional autophagy, as seen by clonogenic long-term growth assays 
(Figure 40C-D). These results suggest that induction of autophagy is a key mechanism by which 
DIRAS1 and DIRAS2 inhibit ovarian cancer cell growth and survival. 
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 DIRAS1 and DIRAS2 
inhibit ovarian cancer cell 
migration. In addition, re-
expression of DIRAS1 and 
DIRAS2 significantly inhibited 
ovarian cancer cell migration. 
SKOv3 and Hey ovarian cancer 
cells were transiently transfected 
with pLoc-DIRAS family 
plasmids, and seeded in a 96-
well format using the Oris Cell 
migration assay. A round wound 
was formed by the stopper which 
was subsequently removed and 
cell migration was tracked for 20 
hours. GFP-positive cells were 
quantified and used to control for 
transfection efficiency. I 
documented a significant 
decrease in migration upon re-
expression of all three DIRAS 
family members (Figure 41). 
Figure 40. DIRAS1- and DIRAS2-induced growth 
inhibition is dependent upon functional autophagy.  
Using CRISPR/cas9 double nickase control plasmid or 
Atg5 sgRNA, OVCAR8-DIRAS1 and OVCAR8-DIRAS2 
inducible cells were generated. A-B. Western blot 
analysis revealed that control cells induced autophagy 
upon re-expression of DIRAS1 or DIRAS2 whereas Atg5 
-/- cells did not. Knockout efficiency was determined by 
western blot analysis of Atg5. C-D. Clonogenic assays 
were performed with these sublines, documenting that 
growth inhibition seen by re-expressing DIRAS1 or 
DIRAS2 is dependent upon functional autophagy. 
Experiments were completed in duplicate. Asterisk 
denotes significant difference (*p<0.05 or **p<0.01). 
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Figure 41. DIRAS family members inhibit ovarian cancer cell migration. A. SKOv3 
ovarian cancer cells transfected with pLoc-DIRAS family member plasmids and an empty 
vector control were assessed for migration potential 20 hours after the removal of a rubber 
boundary. GFP-positive (transfected) cells were imaged and quantified. B. Similar studies 
were conducted with Hey-A8 ovarian cancer cells. C. Representative image following 
quantification of migration into the center well space. Each experiment was completed with 
technical triplicates and performed at least three times. Asterisk denotes significant 
difference (*p<0.05 or **p<0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
DIRAS1 and DIRAS2 induce autophagy by inhibiting the PI3K and Ras/MAPK 
signaling pathways resulting in nuclear localization of autophagy-related 
transcription factors FOXO3a and TFEB. 
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 Under nutrient poor or stressful conditions including hypoxia and DNA damage, 
autophagy is induced to maintain cellular homeostasis. One of the mechanisms by which 
autophagy is induced involves upregulation of transcription factors forkhead box O3 (FOXo3a) 
and transcription factor EB (TFEB) that regulate expression of several autophagy related 
proteins. When FOXo3a is phosphorylated by AKT, it is shuttled out of the nucleus where it is 
bound by 14-3-3 and degraded. Inhibition of the PI3K/AKT signaling pathway results in increased 
nuclear accumulation of FOXo3a and increased transcription of MAPLC3, Gabarap, Atg5 and 
Atg12, VPS34, Beclin1, BNIP3 and Rab7. (Miranda, Mickle et al. 2009, Vellai 2009, Zhou, 
Deng et al. 2009, Mukherjee, 
Ray et al. 2010) In starved cells, 
TFEB becomes 
dephosphorylated and 
translocated to the nucleus 
where it initiates transcription of 
key autophagy-related genes 
including MAPLC3, SQSTM1, 
UVRAG and LAMP1a (Figure 
42). (Settembre and Ballabio 
2011)  
Re-expression of 
DIRAS1 or DIRAS2 inhibits 
phosphorylation of AKT, mTOR, 
and ERK. To determine the 
mechanism by which DIRAS1 
and DIRAS2 induce autophagy I 
first observed the effect of re-
Figure 42. Cartoon documenting the nuclear 
localization and transcriptional activation of 
autophagy-related genes by FOXO3a and TFEB. Upon 
activation of PI3K/AKT and Ras/MAPK signaling 
pathways transcriptional activation of autophagy by 
FOXo3a and TFEB is repressed. AKT phosphorylation 
results in nuclear localization and shuttling of p-FOXo3a 
from the nucleus where it is bound by 14-3-3 and 
degraded. Inhibition of AKT results in increased nuclear 
FOXo3a which can activate gene transcription. AMPK 
can also stimulate FOXo3a-induced transcription of 
autophagy-related genes. Ras/MAPK signaling activation 
and inhibition of TSC1/2 results in increased 
phosphorylation of TFEB keeping in the in nucleus. When 
these signals are reversed, TFEB gets de-
phosphorylated when it can enter the nucleus and bind to 
a CLEAR domain where it activates transcription of 
several autophagy-related genes. 
 
85 
    
expressing DIRAS1 and DIRAS2 on both the 
phosphoinositide 3-kinase (PI3K) and Ras/MAP 
kinase signaling pathways. Re-expression of 
DIRAS1 and DIRAS2 significantly inhibited S473 
AKT phosphorylation, S2448 mTOR 
phosphorylation and 42/44 ERK phosphorylation 
24 hours after gene expression (Figure 43).  
Constitutively active AKT inhibits the 
induction of autophagy which is induced upon re-
expression of DIRAS1 or DIRAS2. The 
phosphoinositide 3-kinase/AKT/mTOR signaling 
pathway is a critical signaling node which impacts 
the induction of autophagy. To examine the 
functional interaction of DIRAS1 and DIRAS2 with 
the PI3K/AKT/mTOR signaling pathway, dominant-
negative AKT (AKT-DN) which contains three point 
mutations, S473A, T308A and K179A and 
constitutively active (AKT-CA) which contains two 
point mutations, S473D and T308D plasmids were 
transfected into OVCAR8-inducible cells. Re-
expression of DIRAS1 or DIRAS2 increased LC3 punctae as determined by immunofluorescence 
staining, and this could be inhibited in cells transfected with constitutively active AKT (Figure 
44). Transfection of dominant negative AKT had no effect on DIRAS1- or DIRAS2-induced 
autophagy as determined by LC3 punctae formation (Figure 44), which is consistent with the 
conclusion that autophagy induced by re-expressing the DIRAS family members was, in part, 
regulated by the PI3K pathway.  
Figure 43. Re-expression of 
DIRAS1 and DIRAS2 inhibit the 
PI3K and Ras/MAPK signaling 
pathways. OVCAR8-inducible cells 
were treated with or without 
doxycycline for 24 hours to induce 
DIRAS1 or DIRAS2 gene expression. 
Cell lysate was collected and western 
blot analysis was performed. Re-
expression of DIRAS1 and DIRAS2 
resulted in a significant decrease in 
p-AKT (S473) and p-ERK (42/44). p-
mTOR (S2488), a downstream target 
of AKT and key inhibitor of autophagy 
was also decreased following re-
expression of DIRAS1 or DIRAS2. 
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DIRAS1 or DIRAS2 enhance nuclear localization of FOXo3a and TFEB. Re-expression 
of DIRAS1- or DIRAS2-increased nuclear localization of autophagy-related transcription factors. 
Figure 44. Autophagy induction by DIRAS1 or DIRAS2 is dependent upon inhibition of 
AKT.  A-B. OVCAR8-DIRAS1 and OVCAR8-DIRAS2 inducible cell lines were seeded at 1.0 
x 105 cells/well in a 2-well chamber slide. Cells were transfected with 1.5µg constitutively 
active AKT (CA-AKT) or dominant negative AKT (DN-AKT) DNA plasmids. Twenty-four  
hours post transfection, DIRAS1 or DIRAS2 expression was induced by the addition of 
doxycycline for 18 hours. Immunofluorescence staining of anti-HA (AKT) and anti-LC3 B 
documented that constitutively active AKT prevented DIRAS1- or DIRAS2-induced 
autophagy. Yellow arrows indicate constitutively active AKT transfected cells without LC3 B 
punctae induced by DIRAS1 or DIRAS2. White arrows indicate cells with endogenous AKT 
which have LC3 B punctae induced by DIRAS1 or DIRAS2. Orange arrows indicate cells 
transfected with dominant negative AKT which also have LC3B punctae induced by DIRAS1 
or DIRAS2. DAPI was used to stain for nuclei. Scale bar 10 µm. 
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Increased nuclear localization of FOXo3a and TFEB was observed by western blot analysis 
(Figure 45A) and immunofluorescence staining following re-expression of the DIRAS family 
members (Figure 45B). Alpha-tubulin and PARP were used as cytoplasm and nuclear extract 
controls, 
respectively, for the 
western blot 
analysis. Using 
quantitative real 
time polymerase 
chain reaction 
(qRT-PCR) I 
observed 
significant 
transcriptional 
upregulation of 
several key 
autophagy-related 
genes including: 
MAP-LC3 B, ULK1, 
Rab7, Gabarap, 
Beclin1 and 
Lamp1a (Figure 
46A-B) at 24 hours 
post re-expression 
of DIRAS1 or 
DIRAS2. The same 
Figure 45. Re-expression of DIRAS1 or DIRAS2 results in nuclear 
localization of FOXo3a and TFEB.  OVCAR8-inducible cells were 
treated with or without DOX for 18 hours. A. Cell lysate was collected 
and western blot analysis was performed to examine the nuclear 
localization of FOXo3a or TFEB. Parp and α-Tubulin were used as 
nuclear/cytoplasm extraction controls. B. Immunofluorescence 
staining of FOXo3a and TFEB nuclear localization following re-
expression of DIRAS1 or DIRAS2. Scale bars indicate 10 µm.  
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was true using SKOv3-IP-inducible ovarian cancer cells (Figure 46C-D). However, I did not 
observe a consistent increase in transcriptional regulation for Rab11a, Atg4, Atg12 or Bnip1 (data 
not shown). Knockdown of FOXo3a or TFEB by transient siRNA transfection resulted in 
decreased autophagy following re-expression of DIRAS1 and DIRAS2 compared to cells 
transfected with control siRNA, as observed by western blot analysis of p62 and LC3B (Figures 
47A-B). Similarly, Ie observed that knockdown of FOXo3a or TFEB in OVCAR8-inducible ovarian 
Figure 46. Re-expression of DIRAS1 or DIRAS2 increases transcription of autophagy 
related genes. OVCAR8- and SKOv3-inducible cell lines were treated with or without 
doxycycline for 24 hours to induce gene expression of DIRAS1 or DIRAS2. mRNA 
expression of LC3B, ULK1, Rab7, Gabarap, Beclin1, and Lamp1a was measured by qRT-
PCR. A. Re-expression of DIRAS1 in OVCAR8 ovarian cancer cells increased mRNA 
expression of ULK1, Rab7, Gabarap, Beclin1 and Lamp1a. B. Re-expression of DIRAS2 in 
OVCAR8 increases mRNA expression of LC3B, ULK1, Rab7, Gabarap, and Beclin1. Similar 
results were obtained for SKOv3-DIRAS1 (C) and SKOv3-DIRAS2 (D).  Column indicates 
the mean and bars indicate the s.d. Significance denoted by the asterisk (*p<0.05, **p<0.01). 
Each experiment was completed at least three times with technical replicates. 
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cancer cell lines inhibited the transcription-mediated upregulation of several key autophagy-
related proteins (Figure 47C-D). Interestingly, knockdown of FOXo3a and TFEB had differential 
effects suggesting that some compensatory mechanisms might facilitate survival following loss 
of these regulators of autophagy.
Figure 47. Knockdown of FOXo3a or TFEB inhibits autophagy induced by re-
expression of DIRAS1 and DIRAS2. OVCAR8-inducible cells were transfected with siRNA 
against FOXo3a and TFEB for 18 hours prior to treatment with or without DOX for 18 hours 
to induce gene expression. A-B. Western blot analysis documents the knockdown efficiency, 
autophagic flux and re-expression of DIRAS1 or DIRAS2. C-D. Quantitative RT-PCR 
quantification of mRNA expression of autophagy-related genes. Column indicates the mean 
and bars indicate the s.d. Significance denoted by the asterisk (*p<0.05, **p<0.01). Each 
experiment was completed at least three times with technical duplicates. 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 8 
DIRAS1 and DIRAS2 serve as surrogates for DIRAS3 in the murine genome. 
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 Since DIRAS3 was lost during telomeric chromosomal rearrangement (Figure 48A) in 
the murine genome (Fitzgerald and Bateman 2004), some 60 million years ago, we hypothesized 
that DIRAS1 or DIRAS2 may serve as surrogates for DIRAS3, playing an essential role in the 
induction of autophagy. DIRAS3 maps to an apparent evolutionary breakpoint in which the 
Figure 48. DIRAS3 was lost in the murine genome following chromosomal re-
arrangement, but DIRAS1 and DIRAS2 are conserved across species. A. Mapping of 
the DIRAS3 gene locus and flanking regions, and the corresponding region in the mouse 
genome. The break in synteny between MMU6 and MMU3 telomeres at the DIRAS3 locus 
is 269 kb. B. Comparison of human and murine DIRAS1 and DIRAS2 protein sequences. 
Amino acids are designated according to the single letter code. An * (asterisk) indicates 
positions which have a single, fully conserved residue. A : (colon) indicates conservation 
between groups of strongly similar properties. A . (period) indicates conservation between 
groups of weakly similar properties. 
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murine genome was re-arranged relative to humans, and is one of several genes in the human 
but not in the murine genome, including COL21A1, STK17A and GPF145. (Fitzgerald and 
Bateman 2004) Mapping of the DIRAS3 locus and flanking regions compared to the 
corresponding region of the mouse genome identified that murine chromosomes 6 and 3 align 
with genes on either side of DIRAS3. The break in synteny between MMU6 and MMU3 telomeres 
at the DIRAS3 locus is 269 kb. Murine DIRAS1 and DIRAS2 are 94% and 99%, respectively, 
homologous to the homo sapien proteins, mainly differing at the C-terminus (Figure 48B).  
Re-expression of DIRAS1 or DIRAS2 induces growth inhibition and autophagy in murine 
ovarian cancer cells. To determine whether DIRAS1 and DIRAS2 have some of the functions of 
DIRAS3, I measured the ability of DIRAS1 and DIRAS2 to inhibit cell growth and to induce 
autophagy in murine ovarian cancer cells. Transient overexpression of murine DIRAS1 and 
DIRAS2 resulted in long term growth inhibition of TBR2, ID8, IG10 and TKOOV10 murine ovarian 
cancer cell lines (Figure 49). A similar result was obtained using NIH3T3 murine fibroblasts (data 
Figure 49. Transient expression of murine DIRAS1 or DIRAS2 inhibits murine 
ovarian cancer cell clonogenic growth. Long term clonogenic growth was assessed 
following transient overexpression of murine DIRAS1 and DIRAS2 in ID8 (A), IG10 (B), 
TBR2 (C) and TKOOV10 (D) murine ovarian cancer cell lines. Selection was performed 
with G418 for two weeks until colonies reached at least 50 cells in size. Columns represent 
the mean and bars represent the S.D. The experiment was performed at least two 
independent times. Asterisk denotes significant difference (**p<0.01). 
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not shown) documenting that growth inhibition following overexpression of DIRAS1 and DIRAS2 
is true for both normal and malignant murine cell lines. Transient overexpression of murine 
DIRAS1 or DIRAS2 resulted in reduction of p62 and increased conversion of LC3 I to LC3 II, 
which was further confirmed by the addition of chloroquine (Figure 50) in a panel of four murine 
ovarian cancer cell 
lines. This data is 
consistent with the 
previously described 
increase in 
autophagic flux 
observed in human 
ovarian cancer cell 
lines following re-
expression of DIRAS1 
or DIRAS2. Induction 
of autophagy was 
confirmed using 
ultrastructural studies 
with transmission 
electron microscopy 
(TEM) where I detected scattered classical double membrane vacuolar structures at 18 hours 
post transfection of murine DIRAS1 or DIRAS2. Typical autophagosomes containing multiple 
lamellae, intact cytoplasmic structures and residual digested materials were also identified. 
(Figure 51). Previous work from the Bast lab documented the essential role of DIRAS3 in 
autophagy. Knockdown of DIRAS3 expression in ovarian cancer cells or normal ovarian epithelial 
Figure 50. Transient expression of murine DIRAS1 or DIRAS2 
induces autophagy in murine ovarian cancer cells. ID8 (A), IG10 
(B), TBR2 (C) and TKOOV10 (D) murine ovarian cancer cells were 
seeded at 0.3 x 106 cells per well and transfected with empty vector, 
DIRAS1 or DIRAS2 plasmid DNA and treated with or without 
chloroquine (5 µm) for 24 hours prior to lysing and immunoblotting as 
indicated. Densitometry was measured with ImageJ and experiments 
were performed at least three times. Autophagic flux was determined 
by the ratio of LC3II/ LC3I and normalized to the loading control, β-
actin.  
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scrapings dramatically reduced autophagy and the formation of autophagic vesicles with or 
without rapamycin treatment to induce autophagy. To determine if DIRAS1 and DIRAS2 were 
required for murine autophagy, I performed similar experiments on cells that were starved of 
amino acids for a period of 2-16 hours. I found that autophagy induced by amino acid starvation 
was inhibited when murine DIRAS1 or murine DIRAS2 was knocked down by siRNA transfection. 
Upon knockdown I saw decreased conversion LC3 I to LC3 II as compared to siRNA control cells 
Figure 51. Transient expression of murine DIRAS1 or DIRAS2 induces classical double 
membrane autophagosomes by electron microscopy. TEM images of ID8 (A) and IG10 
(B) murine ovarian cancer cells were transfected with murine DIRAS1 or DIRAS2 plasmid 
DNA for 18 hours before fixation. A-B. TEM images of ID8 and IG10 cells. Red arrows indicate 
typical double-membrane autophagosomes. Scale bars: 5 µm and 5 nm for close up image.  
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by western blot analysis (Figure 52A) and immunofluorescent staining of LC3 punctae, which 
represent the membrane-bound form of LC3 on autophagic vesicles, suggesting an essential 
role for murine DIRAS1 and DIRAS2 in autophagy (Figure 52B). 
Figure 52. Murine DIRAS1 or DIRAS2 are required for starvation-induced autophagy. 
Mouse ovarian cancer cells were transfected with control, murine DIRAS1 or murine DIRAS2 
siRNA for 72 hours prior to autophagy induction by serum starvation for 4-16 hrs. A. Western 
blot analysis was performed as indicated and documented a decrease in serum starvation 
induced autophagic flux following knockdown of DIRAS1 or DIRAS2. Scale bars indicate 10 
µm B. Immunofluorescence staining of IG10, TBR2, and TKOOV10 cells for LC3 punctae 
following autophagy induction by serum starvation for 16 hours was performed. Quantification 
of punctae/cell was calculated for at least 100 cells per experiment, for three experiments. 
Bars indicate the mean and bars represent the s.d. Significance denoted by the asterisk 
(*p<0.05, **p<0.01) 
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 Manipulation of the genetic code to parse out gene function has been a longstanding 
interest of the scientific community since the discovery of the double helix. Since then, many 
techniques and technologies have been used to induce, overexpress or knockdown genes, and 
subsequently their protein products. Early approaches to introduce site-specific modifications 
depended on the recognition of the DNA by oligonucleotides, self-splicing introns, zinc-finger 
nucleases and TAL effector nucleases or small molecules. Most recently, a discovery of an RNA-
programmable genome engineering system came from understanding the protection 
mechanisms by which bacteria evade phage. Known as CRISPR-Cas9, this technology 
originates from type II CRISPR-Cas systems, where the endonuclease, Cas9, introduces site-
specific double-strand breaks in the DNA based on a guide sequence within an RNA duplex. This 
system has been further simplified, where a single guide RNA (sgRNA) can be engineered, 
replacing the dual tracrRNA:crRNA complex, such that it can bind to DNA at the 5’ side, providing 
specificity to the DNA target site, and it can bind Cas9 at the 3’ side. (Doudna and Charpentier 
2014) This technology is still being developed to better elucidate the homology-directed repair 
mechanisms, which are triggered by the double strand break, with the hypothesis that its 
applications could provide an avenue to successfully revitalize the field of gene therapy. Using 
the CRISPR-Ca9 gene editing system, I created whole genome knockout of DIRAS1 or DIRAS2 
murine embryos (Figure 53) and implanted them into surrogate females. Following several 
backcross generations to eliminate off-target effects, I evaluated the F2 generation offspring for 
genetic and phenotypic effects. I observed that in both cases, germline incorporation had 
occurred but the offspring did not follow Mendelian order, and no homozygous offspring were 
birthed (Figure 53). To determine if the pups were dying in early infancy due to the lack of 
autophagy sustaining life prior to colostrum production, I performed C-sections at gestational day 
18.5 and placed the liter with a surrogate mother, but still no homozygous knockout offspring 
were seen. To determine the day of embryonic lethality, I euthanized pregnant females at several 
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gestational time points, critical for organ development. No homozygous knockout pups were seen 
at 10.5 days or later, suggesting likely early embryonic lethality. As others have previously 
reported, autophagy is increased following fertilization of the egg resulting in stalled development 
of preimplantation mouse embryos which are autophagy deficient. (Tsukamoto, Kuma et al. 
2008)  Further analysis of blasts will be necessary to determine if homozygous loss of DIRAS1 
or DIRAS2 results in an arrested blast phenotype and whether the ability to induce autophagy is 
impaired.
Figure 53. Homozygous deletion of DIRAS1 or DIRAS2 resulted in early embryonic 
lethality. DIRAS1 and DIRAS2 knockout mice were generated using the CRISPR-Cas9 gene 
editing technique. A-B. DNA sequences of murine DIRAS1 and DIRAS2 were assessed for 
presentation of unique PAM sites which could be used to generate specific guide RNAs 
(sgRNAs). The green arrows represent the gene coding sequence and the blue arrows 
represent the protein coding regions. PAM sites are denoted by the black lines. sgRNA 
templates used are listed below the cartoon. C-D. Representative sequencing of F2 
generation offspring is shown with the PAM sequence highlighted in blue. Tables 
documenting the first two litters and their genotypes are listed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 9 
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The DIRAS family members have been identified as ovarian cancer tumor suppressors 
and inhibitors of Ras-induced transformation. These Ras-related small GTPases have an N-
terminal extension, which distinguishes them from other members of the Ras superfamily. 
Previous studies report that DIRAS3, the best characterized of the DIRAS family, is 
downregulated in multiple tumor types including lung, pancreatic, thyroid, breast and ovarian 
cancer where its expression is associated with increased progression-free survival.  (Weber, 
Aldred et al. 2005, Yu, Luo et al. 2006, Dalai, Missiaglia et al. 2007, Huang, Lin et al. 2009, Lin, 
Cui et al. 2011, Wu, Liang et al. 2013) As DIRAS3 was lost from the murine genome ~60 million 
years ago, classical knockout experiments have not been feasible to demonstrate its function as 
a murine tumor suppressor. (Fitzgerald and Bateman 2004) Experiments performed above have 
documented, for the first time, that DIRAS3, as well as DIRAS1 and DIRAS2, can suppress 
transformation of NIH3T3 murine fibroblasts and partially transformed MCF10a breast epithelial 
cells by RasG12V.  
DIRAS1, DIRAS2 and DIRAS3 serve as natural antagonists of Ras/MAPK signaling, likely 
by direct binding and disruption of Ras-Ras association and multimerization. While many tumor 
suppressors have been shown to regulate oncogenesis through mechanisms including cell cycle 
arrest, programmed cell death, repairing DNA damage and inhibiting metastasis, to my 
knowledge this is the first instance where a tumor suppressor protein binds directly to an 
oncogene protein to reverse oncogenic function, In this dissertation, I demonstrate that re-
expression of DIRAS3 inhibits clonogenic growth of Ras-dependent cancer cells across multiple 
cancer types, including cancers that originate in the pancreas, lung and ovary. Growth inhibition 
is associated with decreased p-ERK signaling and knockdown of endogenous DIRAS3 can 
reverse this phenotype. As Ras mutations are found in approximately 30% of all cancer cases 
and increased reports describe downregulation of DIRAS3 across multiple tumor sites, these 
data suggest that greater understanding of this signaling axis may provide novel therapeutic 
opportunities to target mutant Ras. My observations revealed that the 34-amino acid N-terminal 
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extension of DIRAS3 is not required for binding, but is critical for inhibiting transformation, for 
disrupting Ras clusters, as well as for the tumor suppressive functions previously reported. I 
documented that this antagonistic relationship may be related to the interaction of DIRAS3 and 
K-Ras on the plasma membrane. Using immunoprecipitation, Duo-link in-situ hybridization, 
peptide-array analysis, split-luciferase complementation, immunofluorescence, STORM and 
gold-labeled EM, we identified co-localization of DIRAS3 and K-Ras on the plasma membrane. 
While blocking of transformation, inhibition of clonogenic growth and induction of autophagy 
required both the N-terminus and CAAX membrane anchoring domain of DIRAS3, binding of 
DIRAS3 to Ras was dependent upon the CAAX membrane anchoring domain of DIRAS3, but 
did not require the N-terminus or the myristolation site found in the N-terminal extension. Addition 
of the N-terminus from DIRAS3 directly to the N-terminal end of mutant Ras can inhibit oncogenic 
function and downstream effector signaling, highlighting the importance of the N-terminus for 
suppressor function. Using murine fibroblasts and human epithelial cells, I demonstrated that 
DIRAS3 can suppress transformation driven by mutant H- or K-Ras, and both the N-terminal 
extension and CAAX membrane anchoring domains are necessary for the suppression. Although 
the precise mechanism by which this N-terminal region antagonizes Ras function remains 
unclear, my data suggest several potential possibilities including increased stabilization of the 
protein-protein interactions, trafficking to an alternative location on the plasma membrane, 
disruption of Ras-effector binding, or altering the GTP-bound state of Ras, through GEFs, GAPs, 
or by altering intrinsic GTPase activity. Future work to determine the membrane localization 
dynamics following nucleoside exchange, and other Ras-protein interactions will be critical to 
determine the therapeutic potential of targeting mutant Ras. 
My studies demonstrate for the first time that DIRAS3 can disrupt Ras multimerization 
and clustering, associated with decreased Ras signaling through ERK. Although recent work has 
indicated GTP activation following Ras dimerization and many previous reports have shown 
increased signaling with constitutively active Ras, it is not clear whether the number of Ras 
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multimers is directly correlated with the amount of GTP-bound Ras within the cell. (Harmon, 
Nielsen et al. 1985, Nan, Tamguney et al. 2015)  Additional evidence is mounting to suggest that 
oligomerization of Ras at different regions within the plasma membrane results in differential 
functions, suggesting that other effector molecules likely cooperate in the trafficking and spatial 
orientation resulting in activation of this critical signaling axis. (Zhou, Prakash et al. 2017) As 
previously documented, H-Ras or K-Ras increased cluster size when stimulated by EGF, Gal-1, 
mutations of the Ras switch II region, or changes in Ras S181 phosphorylation, associated with 
increased signal output as determined by increased Raf and pErk activity. (Zhou, Liang et al. 
2014, Solman, Ligabue et al. 2015, Zhou, Wong et al. 2015) My data suggest that the inhibition 
of Sos-1 and GTP-bound Ras by DIRAS3 may serve as a critical step in the membrane clustering 
assembly which results in increased effector signaling. 
Distinguishing effectors that regulate Ras-driven signaling in tumors remains a great 
challenge. The interaction between DIRAS3 and Ras provides a novel approach to target this 
signaling axis, which drives multiple malignancies, however, future work to determine the 
mechanism by which DIRAS3 regulates Ras clustering on the plasma membrane is critical to the 
success of translating these findings to clinical therapies. Peptides or small molecules that mimic 
DIRAS3 activity could target the function of mutant Ras directly and specifically, filling a 
significant unmet clinical need for Ras inhibitors.  
 In addition to affecting Ras clustering, I found that DIRAS1 and DIRAS2 also induce 
autophagy at several levels and likely serve as surrogates to DIRAS3 in the murine genome. 
Knockdown of DIRAS1 or DIRAS2 prevents induction of starvation induced autophagy, 
consistent with their being required for murine autophagy, similar to the requirement for DIRAS3 
to induce autophagy in human cells. Under nutrient poor or stressful conditions such as hypoxia 
and DNA damage, autophagy is elicited to help maintain cellular homeostasis. These conditions 
result in a transcriptional response of FOXo3a and TFEB, which trigger transcriptional expression 
of autophagy-related proteins. Re-expression of DIRAS1 or DIRAS2 alters intracellular signaling 
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pathways that favor autophagy. Expression of DIRAS1 or DIRAS2 downregulates both the 
PI3K/AKT and Ras/MAPK pathways, as observed by decreased p-AKT and p-ERK protein 
expression, both of which have downstream effects on mTOR. (He and Klionsky 2010)  
 The significance of this inhibition is underlined by the ability of DIRAS1 or DIRAS2 to 
regulate autophagy by modulating nuclear localization of FOXO3a and TFEB, two master 
regulators of autophagy-related transcription. The dual role of these pathways to maintain cellular 
homeostasis through autophagy regulation is highlighted as upregulation of one pathway occurs 
following reciprocal knockdown with siRNA.  In response to DIRAS1 or DIRAS2 expression, I 
observed increased transcription of LC3B, ULK1, Rab7, Gabarap, Beclin1 and Lamp1a, which 
was dependent upon FOXo3a and TFEB nuclear localization. While DIRAS3 has been shown to 
regulate FOXo3a-mediated upregulation of ATG4, LC3 and Rab7, (Lu, Yang et al. 2014) DIRAS1 
and DIRAS2 increase several additional autophagy-related genes, most notably those involved 
in lysosomal fusion. This is in line with my experimental results which show rapid progression 
through autophagy that is highlighted by a large increase in LC3 II conversion following the 
addition of chloroquine, a lysosomotropic agent which inhibits lysosomal hydrolases and 
prevents autophagosomal fusion and degradation LC3 and the contents of the autophagosome. 
All three members of the DIRAS family have multiple LC3-interacting regions (LIR) domains 
(Kalvari, Tsompanis et al. 2014), but based on my immunofluorescence staining of LC3II and 
DIRAS1 or DIRAS2, there does not seem to be significant co-localization between the two 
proteins, unlike the co-localization of DIRAS3 with LC3II. (Lu, Luo et al. 2008) Co-localization 
with LC3II does not seem to be the only difference between DIRAS1/DIRAS2 and DIRAS3. 
DIRAS3 has been well characterized as a member of the AIC (Lu, Baquero et al. 2014) but 
immunoprecipitation of DIRAS1 or DIRAS2 did not show co-localization with Beclin1 (data not 
shown). While the effect of DIRAS1 and DIRAS2 on Beclin1 homodimerization remains to be 
tested, this direct interaction may account for the weaker induction of autophagy as seen 
following re-expression of DIRAS1 or DIRAS2 compared to DIRAS3, in ovarian cancer cells. As 
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members of the Bast lab previously reported that the N-terminus of DIRAS3 may be important 
for the disruption of Beclin1-Bcl2 interaction, the shorter N-termini of DIRAS1 and DIRAS2 
lacking the leucine-rich, hydrophobic domain might account for the differences in the 
mechanisms by which DIRAS1 and DIRAS2 induce autophagy compared to DIRAS3. 
Genetically engineered mouse models generated by multiple approaches targeting 
autophagy-related genes have been used to better understand mammalian development and 
adult tissue homeostasis. Homozygous depletion of Ambra1, Atg5, and Beclin1, just to name a 
few, resulted in early embryonic lethality, suggesting a key developmental role for autophagy. 
(Qu, Yu et al. 2003, Fimia, Stoykova et al. 2007, Tsukamoto, Kuma et al. 2008) Tsukamoto et. 
al. used mice expressing green fluorescent protein (GFP)-fused LC3 (mammalian Atg8 
homology), to document the induction of autophagy following fertilization, demonstrating how 
maternal proteins in oocytes can be degraded permitting expression of the zygote genome. 
(Tsukamoto, Kuma et al. 2008) Homozygous deletion of murine DIRAS1 or DIRAS2 resulted in 
early embryonic lethality. While these complex phenotypes may not only represent the role of 
autophagy, but also gene specific functions, they emphasize the importance of DIRAS1 and 
DIRAS2 in murine development. Future studies to determine the long-term phenotypes 
associated with heterozygous loss of DIRAS1 or DIRAS2 are underway. As others have 
previously reported, autophagy is increased following fertilization of the egg resulting in stalled 
development of preimplantation mouse embryos which are autophagy deficient. Based on these 
findings, observation of DIRAS1-/- or DIRAS2-/- embryos from the 2-cell stage and beyond should 
be completed to determine if knockdown of either of these two genes results in halted cell division 
or decreased cellular autophagy.  
Although mutations in key autophagy-related genes are not seen widely across cancers, 
the role of autophagy to suppress tumorigenesis was discovered through loss of Beclin1 in 
breast, ovary and prostate cancers. (Liang, Jackson et al. 1999) In a mouse model, homozygous 
loss of Beclin1 resulted in prenatal lethality and heterozygous loss of Beclin1 resulted in 
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premature death, reduced autophagy and an increased incidence of lung carcinomas, 
hepatocellular carcinomas and lymphomas. (Yue, Jin et al. 2003) These data provide evidence 
that autophagy could serve as a tumor suppressive mechanism. Similarly, many other well 
characterized tumor suppressors, such as PTEN, AMPK, LKB1 and TSC1/2 all negatively 
regulate the protein kinase target of rapamycin (mTOR) and induce autophagy. The overlap in 
signaling cascades between regulation of autophagy and the control of cancer, provide 
mechanisms by which tumor suppressors and oncogenes can participate in this process, and 
adds to the complexity of the role of autophagy in oncogenesis. On the one hand, inhibition of 
autophagy has been shown to promote oxidative stress, genomic instability and oncogenesis, 
while on the other, autophagy protects the cancer cell from hypoxia and nutrient starvation which 
can promote resistance to chemotherapy in established tumors. (Avalos, Canales et al. 2014) In 
all cases, the induction of autophagy by mTOR inhibition seems to be a pivotal step leading to 
the digestion of cytoplasmic contents.  
 Consistent with the role of autophagy as a tumor suppressive mechanism, DIRAS1 and 
DIRAS2 protein expression correlated with both increased overall and progression-free survival 
in a cohort of ovarian cancer patients, whereas DIRAS3 downregulation was only associated 
with progression-free survival. Unlike DIRAS3, DIRAS1 and DIRAS2 are not imprinted genes, so 
the extent of downregulation may be less frequent where two hits are required. Future studies of 
the mechanisms by which DIRAS1 and DIRAS2 are downregulated needs to be performed. To 
this extent, sequence predictions document that miR221 and miR222 would likely recognize all 
three DIRAS family members and therefore one would hypothesize that those cases where 
DIRAS3 is downregulated by this mechanism might also show downregulation of DIRAS1 and 
DIRAS2. Immunohistochemical staining analysis of DIRAS1 and DIRAS2 across normal organs 
suggest differential expression, however all three DIRAS family members had relatively strong 
expression in normal pancreas, breast, kidney and adrenal gland. As DIRAS3 is downregulated 
in multiple tumor types, there may be a potential tumor suppressive role for DIRAS1 and DIRAS2 
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in other cancers, providing another avenue worth future exploration. DIRAS3-induced autophagy 
has been implicated in the induction of tumor dormancy in vivo, further studies to characterize 
the role of DIRAS1 or DIRAS2 as they relate to tumor dormancy could provide additional models 
and greater understanding of this process which often results in untreatable, resistant disease.  
 In conclusion, the data presented tested the hypothesis that the DIRAS family members 
inhibit Ras activity by binding directly to Ras and disrupting Ras multimerization. More specifically 
documenting that the N-terminus and CAAX membrane anchoring domain of DIRAS3 are 
essential for the suppressive function observed, highlighting a novel mechanism of tumor 
suppression which depends on direct interaction and antagonism of an oncogene. The N-
terminus of DIRAS3 also plays a critical role in the mechanism(s) by which DIRAS3 induces 
autophagy. I also tested the hypotheses that DIRAS1 and DIRAS2 share some of the function(s) 
of DIRAS3, serving as ovarian cancer tumor suppressors by inhibiting proliferation and motility 
and inducing autophagic cell death and that they can serve as surrogates for DIRAS3 in the 
murine genome, playing an essential role in murine autophagy. This work establishes the role of 
DIRAS1 and DIRAS2 as tumor suppressors and highlights their importance in the murine 
genome. DIRAS1, 2, and 3, share the ability to inhibit cell proliferation and Ras-driven 
transformation while inducing autophagic cell death in vitro. Mechanistically, DIRAS1 and 
DIRAS2 induce autophagy by inhibition of the Ras/MAPK and PI3K/AKT/mTOR signaling 
pathways and inducing transcriptional activation of autophagy-related genes by FOXo3a and 
TFEB. Differing from DIRAS3, DIRAS1 and DIRAS2 do not appear to be critical members of the 
AIC nor do they co-localize with LC3B by immunofluorescence. Homozygous loss of DIRAS1 or 
DIRAS2 resulted in early embryonic lethality in mice and knockdown of murine DIRAS1 and 
DIRAS2 reduced starvation-induced autophagy in murine ovarian cancer cells. These studies 
demonstrate the importance of the N-terminal and CAAX domains of the DIRAS family members 
and provide novel insight into their tumor suppressive function, as well as their essential role in 
murine autophagy. 
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